Aveo Pharmaceuticals (AVEO) 10-K 22 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 17, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	AVEO
Entity Registrant Name	AVEO PHARMACEUTICALS INC
Entity Central Index Key	1,325,879
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		75,862,946
Entity Public Float			$ 61,056,258

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 15,096	$ 26,634
Marketable securities	8,252	7,501
Accounts receivable	1,027	4,641
Clinical trial retainers	1,702	467
Other prepaid expenses and other current assets	238	1,133
Total current assets	26,315	40,376
Property and equipment, net		23
Clinical trial retainers	940	117
Other assets	30	26
Total assets	27,285	40,542
Current liabilities:
Accounts payable	2,186	1,425
Accrued clinical trial costs and contract research	3,998	1,966
Other accrued liabilities	1,531	2,140
Loans payable, net of discount	2,124	2,053
Deferred revenue	510	814
Settlement liability (Note 15)	4,000	4,000
Total current liabilities	10,349	12,398
Loans payable, net of current portion and discount	11,879	7,418
Deferred revenue	1,697	2,881
Warrant liability (Note 7)	4,593
Other liabilities	690	618
Total liabilities	29,208	23,315
Stockholders' (deficit) equity:
Preferred stock, $.001 par value: 5,000 shares authorized at each of December 31, 2016 and 2015; no shares issued and outstanding at each of December 31, 2016 and 2015
Common stock, $.001 par value: 200,000 shares authorized at each of December 31, 2016 and 2015; 75,863 and 58,182 shares issued and outstanding as of December 31, 2016 and 2015, respectively	76	58
Additional paid-in capital	519,911	512,201
Accumulated other comprehensive income (loss)	6	(3)
Accumulated deficit	(521,916)	(495,029)
Total stockholders’ (deficit) equity	(1,923)	17,227
Total liabilities and stockholders’ (deficit) equity	$ 27,285	$ 40,542

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	75,862,946	58,182,000
Common stock, shares outstanding	75,862,946	58,182,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Collaboration and licensing revenue	$ 2,515	$ 19,024	$ 18,123
Operating expenses:
Research and development	23,703	12,875	38,254
General and administrative	8,205	14,217	18,589
Restructuring and lease exit		4,358	11,729
Operating Expenses, Total	31,908	31,450	68,572
Loss from operations	(29,393)	(12,426)	(50,449)
Other income (expense), net:
Interest expense, net	(1,949)	(2,286)	(2,356)
Change in fair value of warrant liability	4,751
Other (expense) income	(195)	(289)	66
Other income (expense), net	2,607	(2,575)	(2,290)
Net loss before provision for income taxes	(26,786)	(15,001)	(52,739)
Provision for income taxes	(101)
Net loss	$ (26,887)	$ (15,001)	$ (52,739)
Basic and diluted net loss per share:
Net loss per share	$ (0.39)	$ (0.27)	$ (1.01)
Weighted average number of common shares outstanding	69,268	55,701	52,289

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (26,887)	$ (15,001)	$ (52,739)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	9	(3)	2
Comprehensive loss	$ (26,878)	$ (15,004)	$ (52,737)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) $ in Thousands	Total	Private Placement	At-The-Market Sale Agreement	Common Shares	Common SharesPrivate Placement	Common SharesAt-The-Market Sale Agreement	Additional Paid-in Capital	Additional Paid-in CapitalPrivate Placement	Additional Paid-in CapitalAt-The-Market Sale Agreement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2013	$ 69,938			$ 52			$ 497,177			$ (2)	$ (427,289)
Beginning Balance (in shares) at Dec. 31, 2013				51,809,000
Stock-based compensation expense related to equity-classified awards | Equity-classified awards	2,750						2,750
Issuance of common stock to settle liability-classified share awards granted to directors (in shares) | Liability Classified Awards				31,000
Issuance of common stock to settle liability-classified share awards granted to directors | Liability Classified Awards	51						51
Issuance of common stock under employee stock purchase plan (in shares)				139,000
Issuance of common stock under employee stock purchase plan	191			$ 139			191
Issuance of warrants in connection with loans payable	413						413
Issuance of restricted stock awards, net of forfeitures				310,000
Change in unrealized gain (loss) on investments	2									2
Net loss	(52,739)										(52,739)
Ending Balance at Dec. 31, 2014	20,606			$ 52			500,582				(480,028)
Ending Balance (in shares) at Dec. 31, 2014				52,289,000
Stock-based compensation expense related to equity-classified awards | Equity-classified awards	1,132						1,132
Exercise of stock options (in shares)				166,000
Exercise of stock options	241						241
Issuance of common stock to settle liability-classified share awards granted to directors (in shares) | Liability Classified Awards				8,000
Issuance of common stock to settle liability-classified share awards granted to directors | Liability Classified Awards	7						7
Issuance of common stock under employee stock purchase plan (in shares)				7,000
Issuance of common stock under employee stock purchase plan	27						27
Issuance of common stock (in shares)						5,913,000
Issuance of common stock			$ 10,218			$ 6			$ 10,212
Forfeiture of restricted stock awards (in shares)				(201,000)
Change in unrealized gain (loss) on investments	(3)									(3)
Net loss	(15,001)										(15,001)
Ending Balance at Dec. 31, 2015	$ 17,227			$ 58			512,201			(3)	(495,029)
Ending Balance (in shares) at Dec. 31, 2015	58,182,000			58,182,000
Issuance of common stock and warrants in a private placement, excluding to related parties, net (in shares)					17,098,000
Issuance of common stock and warrants in a private placement, excluding to related parties, net		$ 14,846			$ 17			$ 14,829
Issuance of common stock and warrants to related parties (in shares)				544,000
Issuance of common stock and warrants to related parties	$ 525			$ 1			524
Stock-based compensation expense related to equity-classified awards | Equity-classified awards	999						999
Issuance of warrants in connection with a private placement	$ (9,344)						(9,344)
Exercise of stock options (in shares)	38,749			39,000
Exercise of stock options	$ 33						33
Issuance of common stock under employee stock purchase plan	2						2
Issuance of warrants in connection with loans payable	667						667
Change in unrealized gain (loss) on investments	9									9
Net loss	(26,887)										(26,887)
Ending Balance at Dec. 31, 2016	$ (1,923)			$ 76			$ 519,911			$ 6	$ (521,916)
Ending Balance (in shares) at Dec. 31, 2016	75,862,946			75,863,000

Consolidated Statements of Sto7

Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) - Additional Paid-in Capital - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
At-The-Market Sale Agreement
Issuance of common stock, issuance costs		$ 157
Private Placement
Issuance of common stock, issuance costs	$ 1,600

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating activities
Net loss	$ (26,887)	$ (15,001)	$ (52,739)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of property and equipment		232	7,600
Depreciation and amortization	30	9,567	6,219
Net loss (gain) on disposal of fixed assets		253	(127)
Stock-based compensation	999	1,132	2,808
Non-cash interest expense	465	655	347
Non-cash change in fair value of warrant liability	(4,751)
Amortization of premium and discount on investments	14	34	221
Changes in operating assets and liabilities:
Restricted Cash		2,997	598
Accounts receivable	3,614	(2,300)	(1,357)
Tenant improvement allowance receivable			5,833
Prepaid expenses and other current assets	(340)	(116)	1,503
Other noncurrent assets	(827)	96	50
Accounts payable	760	(1,820)	(993)
Accrued clinical trial costs and contract research	2,032	(3,562)	(1,153)
Other accrued liabilities	(609)	(1,627)	(911)
Settlement liability	(4,000)	4,000
Deferred revenue	(1,488)	2,927	(17,623)
Lease exit obligation		(5,206)	4,981
Deferred rent		(10,569)	(9,505)
Other liabilities	(78)	78	0
Net cash used in operating activities	(31,066)	(18,230)	(54,248)
Investing activities
Purchases of marketable securities	(29,421)	(19,085)	(42,306)
Proceeds from maturities and sales of marketable securities	28,664	11,550	109,767
Purchases of property and equipment	(7)	(22)	(12,942)
Proceeds from sale of property and equipment		1,241	191
Net cash (used in) provided by investing activities	(764)	(6,316)	54,710
Financing activities
Proceeds from issuance of common stock and warrants, net of issuance costs	14,846	10,218
Proceeds from issuance of common stock and warrants to related parties	525
Proceeds from issuance of loan payable and warrants	5,000		10,000
Proceeds from issuance of stock for stock-based compensation arrangements	36	268	191
Payments of debt issuance costs	(115)		(1,388)
Principal payments on loans payable		(11,612)	(7,785)
Net cash provided by (used in) financing activities	20,292	(1,126)	1,018
Net (decrease) increase in cash and cash equivalents	(11,538)	(25,672)	1,480
Cash and cash equivalents at beginning of period	26,634	52,306	50,826
Cash and cash equivalents at end of period	15,096	26,634	52,306
Supplemental cash flow information
Cash paid for interest	1,539	$ 1,983	2,018
Non-cash financing activity
Fair value of warrants issued in connection with long term debt	667		$ 413
Fair value of warrants issued in connection with private placement	$ 9,344

Organization

Organization	12 Months Ended
	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization	(1) Organization AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company’s proprietary platform has delivered unique insights into cancer and related diseases. The Company’s strategy is to leverage these biomarker insights and partner resources to advance the development of its clinical pipeline. The Company’s pipeline includes its lead candidate tivozanib, an oral, once-daily, vascular endothelial growth factor (“VEGF”) tyrosine kinase inhibitor (“TKI”). Tivozanib is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications. Tivozanib has been investigated in several tumor types, including renal cell, colorectal and breast cancers In June 2013, the U.S. Food and Drug Administration (“FDA”) issued a complete response letter denying the Company’s application for approval of the use of tivozanib in first-line treatment of advanced renal cell carcinoma (“RCC”), citing concerns regarding the negative trend in overall survival in the Company’s first pivotal phase 3 trial (the “TIVO-1” study). In May 2016, the Company initiated enrollment and treatment of patients in new The Company expects to complete enrollment in the study in June 2017 and to report top line data in the first quarter of 2018. TIVO-3 is also expected to undergo a pre-planned futility analysis approximately mid-year 2017. In March 2017, the Company initiated enrollment in a phase 1/2 trial of tivozanib in combination with Opdivo® (“nivolumab”), an (the “TiNivo” trial) Bristol-Myers Squibb is supplying nivolumab for the TiNivo trial, and the Company is the trial sponsor. The study is being led by the Institut Gustave Roussy in Paris under the direction of Professor Bernard Escudier, MD, Chairman of the Genitourinary Oncology Committee. phase will primarily evaluate phase . In February 2016, EUSA Pharma (UK) Ltd. (“EUSA”), the Company’s European licensee, submitted a Marketing Authorization Application (“MAA”) for tivozanib with the European Medicines Agency (“EMA”) for the treatment of RCC. The EMA validated the MAA in March 2016, confirming that the submission was complete and that it would initiate its review process. EUSA received the Day 120 List of Questions from the Committee for Medicinal Products for Human Use (“CHMP”) of the EMA in July 2016, and submitted its responses in November 2016. In January 2017, EUSA received the Day 180 List of Outstanding Issues (“LOI”) from the CHMP of the EMA. The Day 180 LOI signifies that the MAA is not approvable at the present time, and outlines outstanding deficiencies, which are then required to be satisfactorily addressed in an oral explanation and/or in writing prior to a final application decision. EUSA has informed the Company that it expects to submit written responses to the Day 180 LOI in April 2017, and the EMA has tentatively scheduled EUSA to provide an oral explanation to the CHMP in May 2017. The Company also has a pipeline of monoclonal antibodies, including: (i) Ficlatuzumab, a potent hepatocyte growth factor (“HGF”) antibody that inhibits the activity of the HGF/c-Met pathway. Ficlatuzumab has ongoing clinical trials in acute myloid leukemia (“AML”) and squamous cell cancer of the head and neck. The Company and its worldwide partner Biodesix, Inc (“Biodesix”) will share equally in all future costs and profits relating to the development of ficlatuzumab. (ii) AV-203, a potent, high-affinity inhibitor of the ErbB3 pathway. The Company’s partner CANbridge Life Sciences Ltd. (“CANbridge”) will fund manufacturing and clinical development through proof-of-concept in esophageal squamous cell carcinoma. (iii) AV-380, a potent, humanized IgG1 inhibitory monoclonal antibody targeting growth differentiating factor-15 (“GDF15”), a divergent member of the TGF-ß family, for the potential treatment or prevention of cachexia. The Company has licensed AV-380 to Novartis International Pharmaceutical Ltd. (“Novartis”), which will fund all development, manufacturing and commercialization; and (iv) The AV-353 platform, a family of potent inhibitory antibody candidates specific to Notch 3, one of which has demonstrated an ability in preclinical models to potentially reverse disease phenotype for pulmonary arterial hypertension (“PAH”). The Company is currently seeking a partner to advance development of the AV-353 platform for the potential treatment of PAH. As used throughout these condensed consolidated financial statements, the terms “AVEO,” and the “Company” refer to the business of AVEO Pharmaceuticals, Inc. and its two wholly-owned subsidiaries, AVEO Pharma Limited and AVEO Securities Corporation. Liquidity and Going Concern The Company has financed its operations to date primarily through private placements and public offerings of its common stock and preferred stock, license fees, milestone payments and research and development funding from strategic partners, and loan proceeds. The Company has devoted substantially all of its resources to its drug development efforts, comprising research and development, manufacturing, conducting clinical trials for its product candidates, protecting its intellectual property and general and administrative functions relating to these operations. The Company is subject to a number of risks, including the need for substantial additional capital for clinical research and product development and the risk that it is unable to maintain compliance with its financial covenant pursuant to its Loan Agreement with Hercules, which requires the Company to maintain unrestricted cash (defined as cash and liquid cash, including marketable securities) greater than or equal to $10.0 million through the date of completion of the Company’s Phase 3 TIVO-3 trial. Refer to Note 6 for further description of the Company’s loan and security agreement. Based upon the Company’s approximately $23.3 million in existing cash, cash equivalents and marketable securities as of December 31, 2016, the Company does not have sufficient existing cash, cash equivalents and marketable securities to support operations and maintain compliance with the financial covenant for at least the next year following the date that the financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s plans to alleviate these conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern include pursuing one or more of the following steps to raise additional funding, none of which can be guaranteed or are entirely within the Company’s control: • Raise funding through the possible sales of the Company’s common stock, including public or private equity financings. • Raise funding through the possible sales of the Company’s common stock under the at-the-market issuance sales agreement (the “Sales Agreement”) with FBR & Co. (formerly MLV & Co. LLC) (“FBR”), as discussed in Note 7. • Raise funding under the Company’s loan and security agreement (the “Loan Agreement”) with Hercules Technology II, L.P. and Hercules Technology III, L.P., affiliates of Hercules Technology Growth (collectively, “Hercules”), which, as described in Note 6, provides access to additional funding only if certain specified conditions are met. • Continue to seek a partner to advance development of the AV-353 platform for the potential treatment of PAH. • Earn milestone payments pursuant to collaboration and license agreements described in Note 4 or restructure / monetize existing potential milestone and/or royalty payments under those collaboration and license agreements. There can be no assurance, however, that the Company will receive cash proceeds from any of these potential resources or, to the extent cash proceeds are received, those proceeds would be sufficient to support the Company’s operations and allow the Company to maintain compliance with its financial covenant for at least the next year following the date that the financial statements are issued. Management has concluded the likelihood that its plan to obtain sufficient funding from one or more of these sources will be successful, while reasonably possible, is less than probable. Accordingly, management has concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern. If the Company is unable to raise capital when needed or on attractive terms, or if it is unable to procure partnership arrangements to advance its programs, or if it is unable to maintain compliance with the financial covenant in the loan and security agreement, the Company would be forced to delay, reduce or eliminate its research and development programs and any future commercialization efforts. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	(2) Basis of Presentation These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, AVEO Pharma Limited and AVEO Securities Corporation. The Company has eliminated all significant intercompany accounts and transactions in consolidation. Certain reclassifications have been made to prior periods to conform to current period presentation. Reclassification of prior year amounts have been made to separately present clinical trial retainers from other prepaid expenses and other current assets, and other non-current assets, and accrued clinical trial costs and contract research from other accrued liabilities on the consolidated balance sheets and to present interest expense net of interest income on the consolidated statements of operations. There was no impact on total liabilities, total other expenses or net income (loss) resulting from these reclassifications.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies	(3) Significant Accounting Policies Revenue Recognition The Company’s revenues are generated primarily through collaborative research, development and commercialization agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses, or options to obtain licenses, to the Company’s technology, (ii) research and development activities to be performed on behalf of the collaborative partner, and (iii) in certain cases, services in connection with the manufacturing of pre-clinical and clinical material. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; milestone payments; and royalties on future product sales. When evaluating multiple element arrangements, the Company considers whether the deliverables under the arrangement represent separate units of accounting. This evaluation requires subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separable from the other aspects of the contractual relationship. In determining the units of accounting, management evaluates certain criteria, including whether the deliverables have standalone value, based on the relevant facts and circumstances for each arrangement. The consideration received is allocated among the separate units of accounting using the relative selling price method, and the applicable revenue recognition criteria are applied to each of the separate units. The Company determines the estimated selling price for deliverables within each agreement using vendor-specific objective evidence (“VSOE”) of selling price, if available, third-party evidence (“TPE”) of selling price if VSOE is not available, or best estimate of selling price if neither VSOE nor TPE is available. Determining the best estimate of selling price for a deliverable requires significant judgment. The Company typically uses best estimate of selling price to estimate the selling price for licenses to the Company’s proprietary technology, since the Company often does not have VSOE or TPE of selling price for these deliverables. In those circumstances where the Company utilizes best estimate of selling price to determine the estimated selling price of a license to the Company’s proprietary technology, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements and internally developed models that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the Company’s best estimate of selling price, the Company evaluates whether changes in the key assumptions used to determine the best estimate of selling price will have a significant effect on the allocation of arrangement consideration among multiple deliverables. The Company typically receives non-refundable, upfront payments when licensing its intellectual property in conjunction with a research and development agreement. When management believes the license to its intellectual property does not have stand-alone value from the other deliverables to be provided in the arrangement, the Company generally recognizes revenue attributed to the license on a straight-line basis over the Company’s contractual or estimated performance period, which is typically the term of the Company’s research and development obligations. If management cannot reasonably estimate when the Company’s performance obligation ends, then revenue is deferred until management can reasonably estimate when the performance obligation ends. When management believes the license to its intellectual property has stand-alone value, the Company generally recognizes revenue attributed to the license upon delivery. The periods over which revenue should be recognized are subject to estimates by management and may change over the course of the research and development agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Payments or reimbursements resulting from the Company’s research and development efforts for those arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis so long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is reasonably assured. Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance, and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. The Company aggregates its milestones into four categories: (i) clinical and development milestones, (ii) regulatory milestones, (iii) commercial milestones, and (iv) patent-related milestones. Clinical and development milestones are typically achieved when a product candidate advances into a defined phase of clinical research or completes such phase. For example, a milestone payment may be due to the Company upon the initiation of a phase 3 clinical trial for a new indication, which is the last phase of clinical development and could eventually contribute to marketing approval by the FDA or other global regulatory authorities. Regulatory milestones are typically achieved upon acceptance of the submission for marketing approval of a product candidate or upon approval to market the product candidate by the FDA or other global regulatory authorities. For example, a milestone payment may be due to the Company upon the FDA’s acceptance of a New Drug Application (“NDA”). Commercial milestones are typically achieved when an approved pharmaceutical product reaches certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount. Patent-related milestones are typically achieved when a patent application is filed or a patent is issued with respect to certain intellectual property related to the applicable collaboration. Revenues from clinical and development, regulatory, and patent-related milestone payments, if the milestones are deemed substantive and the milestone payments are nonrefundable, are recognized upon successful accomplishment of the milestones. The Company has concluded that the clinical and development, regulatory and patent-related milestones pursuant to its current research and development arrangements are substantive. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line basis over the remaining period of performance. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met. Research and Development Expenses Research and development expenses are charged to expense as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including internal costs for salaries, bonuses, benefits, stock-based compensation, facilities, and research-related overhead, and external costs for clinical trials, drug manufacturing and distribution, license fees, consultants and other contracted services. Warrants Issued in Connection with Private Placement In May 2016, the Company issued warrants to purchase an aggregate of 17,642,482 shares of common stock in connection with a private placement financing and recorded the warrants as a liability. The Company accounts for warrant instruments that either conditionally or unconditionally obligate the issuer to transfer assets as liabilities regardless of the timing of the redemption feature or price, even though the underlying shares may be classified as permanent or temporary equity. . These warrants are subject to revaluation at each balance sheet date, and any changes in fair value are recorded as a non-cash component of other income (expense), net until the earlier of their exercise or expiration or upon the completion of a liquidation event. The following table rolls forward the fair value of the Company’s warrant liability, the fair value of which is determined by Level 3 inputs for the year ended December 31, 2016 (in thousands): Fair value at January 1, 2016 $ — Issuance of warrants on May 13, 2016 9,344 Change in fair value (4,751 ) Fair value at December 31, 2016 $ 4,593 Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase and an investment in a U.S. government money market fund to be cash equivalents. Changes in the balance of cash and cash equivalents may be affected by changes in investment portfolio maturities, as well as actual cash disbursements to fund operations. The Company’s cash is deposited in highly-rated financial institutions in the United States. The Company invests in high-grade, short-term corporate bonds and other U.S. government agency securities, which management believes are subject to minimal credit and market risk. Marketable Securities Marketable securities consist primarily of investments which have expected average maturity dates in excess of three months, but not longer than 24 months. The Company invests in high-grade corporate obligations, including commercial paper, and U. S. government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations they are classified as current assets on the consolidated balance sheets. Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. The cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion recorded as a component of interest expense, net. Unrealized gains and losses are included in other comprehensive loss until realized, at which point they would be recorded as a component of interest expense, net. Below is a summary of cash, cash equivalents and marketable securities at December 31, 2016 and December 31, 2015: Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2016 Cash and cash equivalents: Cash and money market funds $ 14,091 $ — $ — $ 14,091 Corporate debt securities 1,005 — — 1,005 Total cash and cash equivalents 15,096 — — 15,096 Marketable securities: Corporate debt securities due within 1 year 8,246 6 — 8,252 Total marketable securities 8,246 6 — 8,252 Total cash, cash equivalents and marketable securities $ 23,342 $ 6 $ — $ 23,348 December 31, 2015: Cash and cash equivalents: Cash and money market funds $ 21,822 $ — $ — $ 21,822 Corporate debt securities 4,812 — — 4,812 Total cash and cash equivalents 26,634 — — 26,634 Marketable securities: Corporate debt securities due within 1 year $ 6,504 $ — $ (3 ) $ 6,501 Government agency securities due within 1 year 1,000 — — 1,000 Total marketable securities 7,504 — (3 ) 7,501 Total cash, cash equivalents and marketable securities $ 34,138 $ — $ (3 ) $ 34,135 Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in highly-rated federally-insured financial institutions in excess of federally insured limits. The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the high credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. The Company’s accounts receivable primarily consists of amounts due to the Company from licensees and collaborators. As of December 31, 2016, the Company had approximately $1.0 million of accounts receivable outstanding, of which approximately $0.8 million was due from Biodesix pursuant to the Company’s collaboration arrangement for ficlatuzumab (refer to Note 4). The Company has not experienced any material losses related to accounts receivable from individual licensees or collaborators. Fair Value Measurements The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. As of December 31, 2016, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a U.S. government money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the year ended December 31, 2016, the Company did not have any transfers of financial assets between Levels 1 and 2. As of December 31, 2016, the Company’s financial liabilities that were recorded at fair value consisted of a warrant liability. The fair value of the Company’s loans payable at December 31, 2016 approximates its carrying value, computed pursuant to a discounted cash flow technique using a market interest rate and is considered a Level 3 fair value measurement. The effective interest rate, which reflects the current market rate, considers the fair value of the warrants issued in connection with the loan, loan issuance costs and the deferred financing charge. The following table summarizes the assets and liabilities measured at fair value on a recurring basis at December 31, 2016 and December 31, 2015: Fair Value Measurements as of December 31, 2016 Level 1 Level 2 Level 3 Total (in thousands) Financial assets carried at fair value: Cash and money market funds $ 14,091 $ — $ — $ 14,091 Corporate debt securities — 1,005 — 1,005 Total cash and cash equivalents $ 14,091 $ 1,005 $ — $ 15,096 Marketable securities: Corporate debt securities due within 1 year — $ 8,252 — $ 8,252 Total marketable securities $ — $ 8,252 $ — $ 8,252 Total cash, cash equivalents and marketable securities $ 14,091 $ 9,257 $ — $ 23,348 Financial liabilities carried at fair value: Warrant liability $ — $ — $ 4,593 $ 4,593 Total warrant liability $ — $ — $ 4,593 $ 4,593 Fair Value Measurements as of December 31, 2015 Level 1 Level 2 Level 3 Total (in thousands) Financial assets carried at fair value: Cash and money market funds $ 21,822 $ — $ — $ 21,822 Corporate debt securities — 4,812 4,812 Total cash and cash equivalents $ 21,822 $ 4,812 $ — $ 26,634 Marketable securities: Corporate debt securities due within 1 year $ — $ 6,501 $ — $ 6,501 Government agency securities due within 1 year — 1,000 — 1,000 Total marketable securities $ — $ 7,501 $ — $ 7,501 Total cash, cash equivalents and marketable securities $ 21,822 $ 12,313 $ — $ 34,135 Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repair costs are charged to expense as incurred. Depreciation expense for the years ended December 31, 2016, 2015 and 2014 was $30 thousand, $9.6 million and $6.2 million, respectively. In September 2014, the Company entered into a Lease Termination Agreement (refer to Note 12). As a result, the Company revised the estimated useful life of its leasehold improvements related to this space, resulting in an increase in depreciation expense of approximately $2.4 million during the year ended December 31, 2014. In February 2015, the Company provided notice that it would surrender the remaining space on May 29, 2015. Accordingly, the Company again revised the estimated useful life of its leasehold improvements related to this office space and amortized such assets through May 2015, resulting in an additional $2.9 million of depreciation expense during the year ended December 31, 2015. Long-lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. The Company recognized $0, $0.2 million and $7.6 million of impairment losses during the years ended December 31, 2016, 2015 and 2014, respectively, primarily related to leasehold improvements. Basic and Diluted Loss per Common Share Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the years ended December 31, 2016, 2015 and 2014, diluted net loss per share is the same as basic net loss per share as the inclusion of weighted average shares of unvested restricted common stock and common stock issuable upon the exercise of stock options and warrants would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive for the years ended December 31, 2016, 2015 and 2014, respectively: Years Ended December 31, 2016 2015 2014 Outstanding stock options 4,858,678 4,796,005 5,817,313 Outstanding warrants 19,453,295 608,696 608,696 Unvested restricted stock — 42,750 477,600 Total 24,311,973 5,447,451 6,903,609 Stock-Based Compensation Under the Company’s stock-based compensation programs, the Company periodically grants stock options and restricted stock to employees, directors and nonemployee consultants. The Company also issues shares under an employee stock purchase plan. The fair value of all awards is recognized in the Company’s statements of operations over the requisite service period for each award. Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. Other awards, such as performance-based awards that vest upon the achievement of specified goals, are expensed using the accelerated attribution method if achievement of the specified goals is considered probable. The Company has also granted awards that vest upon the achievement of market conditions. Per Accounting Standards Codification (“ASC”) 718 Share-Based Payments, The Company uses the Black-Scholes option pricing model to value its stock option awards without market conditions, which require the Company to make certain assumptions regarding the expected volatility its common stock price, the expected term of the option grants, the risk-free interest rate and the dividend yield with respect to its common stock. In 2016, the Company began calculating volatility using its historical data. Previously, the Company did not have sufficient history to support a calculation of volatility using only its historical data. As such, prior to 2016, the Company used a weighted-average volatility considering the Company’s own volatility since March 2010 and the volatilities of several peer companies. For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, similar vesting terms and in-the-money option status. Due to the lack of the Company’s own historical data, the Company elected to use the “simplified” method for “plain vanilla” options to estimate the expected term of the Company’s stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate used for each grant is based on the U.S. Treasury yield curve in effect at the time of grant for instruments with a similar expected life. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. The fair value of equity-classified awards to employees and directors are measured at fair value on the date the awards are granted. Awards to nonemployee consultants are recorded at their fair values and are re-measured as of each balance sheet date until the recipient’s services are complete. During the years ended December 31, 2016, 2015 and 2014, the Company recorded the following stock-based compensation expense: Years Ended December 31, 2016 2015 2014 (in thousands) Research and development $ 293 $ 298 $ 899 General and administrative 706 765 1,909 Restructuring — 69 — Total stock-based compensation expense $ 999 $ 1,132 $ 2,808 Stock-based compensation expense is allocated to research and development and general and administrative expense based upon the department of the employee to whom each award was granted. Expenses recognized in connection with the modification of awards in connection with the Company’s strategic restructurings are allocated to restructuring expense. No related tax benefits of the stock-based compensation expense have been recognized. Income Taxes The Company provides for income taxes using the asset-liability method. Under this method, deferred tax assets and liabilities are recognized based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company calculates its provision for income taxes on ordinary income based on its projected annual tax rate for the year. Uncertain tax positions are recognized if the position is more-likely-than-not to be sustained upon examination by a tax authority. Unrecognized tax benefits represent tax positions for which reserves have been established. Segment and Geographic Information Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment principally in the United States. As of December 31, 2016 and 2015, the Company has $0.8 million and $1.0 million, respectively, of net assets located in the United Kingdom. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the , and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include revenue recognition, contract research accruals, measurement of the warrant liability and measurement of stock-based compensation. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In March 2016, the FASB issued ASU No. 2016-09, Compensation─Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting

Collaborations and License Agre

Collaborations and License Agreements	12 Months Ended
	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborations and License Agreements	(4) Collaborations and License Agreements Out-License Agreements CANbridge In March 2016, the Company entered into a collaboration and license agreement (the “CANbridge Agreement”) with CANbridge Life Sciences Ltd. (“CANbridge”). Under the terms of the CANbridge Agreement, the Company granted CANbridge the exclusive right to develop, manufacture and commercialize AV-203, the Company’s proprietary ErbB3 (HER3) inhibitory antibody, for the diagnosis, treatment and prevention of disease in humans and animals in all countries other than the United States, Canada and Mexico (the “CANbridge Licensed Territory”). Under the terms of the CANbridge Agreement, if the Company determines to grant a license to any ErbB3 inhibitory antibody in the United States, Canada or Mexico, the Company is obligated to first negotiate with CANbridge for the grant to CANbridge of a license to such rights. The effective date of the license agreement is March 16, 2016 (the “Effective Date”). CANbridge made an upfront payment to the Company of $1.0 million in April 2016, net of $0.1 million of withholding taxes. CANbridge has agreed to reimburse the Company $1.0 million for certain manufacturing costs and expenses previously incurred by the Company with respect to AV-203, $0.5 million of which will be due to the Company on the earlier of (i) the date of validation by CANbridge of certain manufacturing development activities conducted by the Company prior to the Effective Date or (ii) twelve months from the Effective Date, and the remaining $0.5 million of which will be due to the Company on the earlier of (i) the date of validation by CANbridge of such manufacturing development activities or (ii) eighteen months from the Effective Date. The Company is also eligible to receive up to $42.0 million in potential development and regulatory milestone payments and up to $90.0 million in potential sales based milestone payments based on annual net sales of licensed products. Upon commercialization, the Company is eligible to receive a tiered royalty, with a percentage range in the low double-digits, on net sales of approved licensed products. CANbridge’s obligation to pay royalties for each licensed product expires on a country-by-country basis on the later of the expiration of patent rights covering such licensed product in such country, the expiration of regulatory data exclusivity in such country and ten years after the first commercial sale of such licensed product in such country. No milestone payments have been earned as of December 31, 2016. CANbridge is obligated to use commercially reasonable efforts to develop and commercialize AV-203 in each of China, Japan, the United Kingdom, France, Italy, Spain, and Germany. CANbridge has responsibility for all activities and costs associated with the further development, manufacture, regulatory filings and commercialization of AV-203 in the CANbridge Licensed Territory. The Company and CANbridge have each agreed to not directly or indirectly develop or commercialize any ErbB3 inhibitory antibody product during the term of the CANbridge Agreement other than pursuant to the CANbridge Agreement. A percentage of any milestone and royalty payments received by the Company, excluding upfront and reimbursement payments, are due to Biogen Idec International GmbH (“Biogen”) as a sublicensing fee under the option and license agreement between the Company and Biogen dated March 18, 2009, as amended. Activities under the CANbridge Agreement Revenue Recognition—Multiple Element Arrangements The CANbridge Agreement includes the following non-contingent deliverables: (i) the Company’s grant of an exclusive license to develop and commercialize AV-203 in the CANbridge Licensed Territory, (ii) the Company’s obligation to transfer all technical knowledge and data useful in the development and manufacture of AV-203 and (iii) the Company’s obligation to participate on a joint steering committee during the proof-of-concept development period. The relative selling price of the Company’s joint steering committee participation had de minimis value. The Company determined that the delivered license and know-how did have stand-alone value from the undelivered element and have accounted for these items as separate deliverables. The Company allocated the upfront consideration of $1.0 million to the units of accounting and recognized the $1.0 million attributed to the delivered license and know-how as revenue during the year ended December 31, 2016. The Company believes the regulatory milestones that may be achieved under the are consistent with the definition of a milestone included in ASC 605-28, Revenue Recognition—Milestone Method , and, accordingly, the Company will recognize payments related to the achievement of such milestones, if any, when each such milestone is achieved. Factors considered in this determination included scientific and regulatory risks that must be overcome to achieve each milestone, the level of effort and investment required to achieve each milestone, and the monetary value attributed to each milestone. EUSA In December 2015, the Company entered into a license agreement with EUSA Pharma (UK) Limited (“EUSA”) Under the license agreement, EUSA made a research and development funding payment to the Company of $2.5 million during the year ended December 31, 2015. EUSA is required to make a further research and development funding payment of $4.0 million if the European Medicines Agency (the “EMA”) grants marketing approval for tivozanib for treatment of RCC. The Company is eligible to receive additional research funding from EUSA, including up to $20.0 million for the Company’s phase 3 study in third-line RCC if EUSA elects to utilize data generated by the study and up to $2.0 million for a phase 1 combination study with a checkpoint inhibitor if EUSA elects to utilize data generated by the study , pursuant to which the Company acquired exclusive rights to develop and commercialize tivozanib for all human diseases outside of Asia and the Middle East. The research and development funding payments under the EUSA license agreement are not subject to sublicensing payment to KHK. EUSA is obligated to use commercially reasonable efforts to seek regulatory approval for and commercialize tivozanib throughout the Activities under the agreement were evaluated under ASC 605-25 to determine whether such activities represented a multiple element revenue arrangement. The agreement with EUSA includes the following non-contingent deliverables: (i) the Company’s grant of an exclusive license to develop and commercialize the tivozanib in the EUSA Licensed Territories; (ii) the Company’s obligation to transfer all technical knowledge and data useful in the development and manufacture of tivozanib; (iii) the Company’s obligation to cooperate with EUSA and support its efforts to file for marketing approval in the EUSA Licensed Territories, (iv) the Company’s obligation to provide access to certain regulatory information resulting from the Company’s ongoing development activities outside of the EUSA Licensed Territories and (v) the Company’s participation in a joint steering committee. The Company determined that the delivered license did not have stand-alone value from the undelivered elements and have accounted for these items as a single bundled deliverable. The Company allocated upfront consideration of $2.5 million to the bundled unit of accounting and is recognizing it over the Company’s performance period through April 2022, the remaining patent life of tivozanib. The Company recognized approximately $0.4 million and $14 thousand as revenue during the years ended December 31, 2016 and 2015, respectively. The Company believes the regulatory milestones that may be achieved under the EUSA agreement are consistent with the definition of a milestone included in ASC 605-28, Revenue Recognition—Milestone Method , and, accordingly, the Company will recognize payments related to the achievement of such milestones, if any, when each such milestone is achieved. Factors considered in this determination included scientific and regulatory risks that must be overcome to achieve each milestone, the level of effort and investment required to achieve each milestone, and the monetary value attributed to each milestone. No milestone payments have been earned as of December 31, 2016. Novartis In August 2015, the Company entered into a license agreement with Novartis. Under the license agreement, the Company has granted to Novartis the exclusive right to develop and commercialize worldwide the Company’s proprietary antibody AV-380 and related AVEO antibodies that bind to GDF15 for the treatment and prevention of diseases and other conditions in all indications in humans (the “Product”). Pursuant to the license agreement, Novartis made an upfront payment to the Company of $15.0 million in September 2015. Novartis also has acquired the Company’s inventory of clinical quality, AV-380 biological drug substance and reimbursed the Company for approximately $3.5 million for such existing inventory. As of December 31, 2016, the Company was also eligible to receive up to $53.0 million in potential clinical and development milestone payments and up to $105.0 million in potential regulatory milestone payments tied to the commencement of clinical trials and to regulatory approvals of products developed under the license agreement in the United States, the European Union and Japan, and it is eligible to receive up to $150.0 million in potential commercial milestone payments based on annual net sales of such products. Upon commercialization, the Company is eligible to receive tiered royalties on net sales of approved products ranging from the high single digits to the low double-digits. Certain milestones achieved by Novartis or timelines associated with the development plan would trigger milestone payment obligations from the Company to St. Vincent’s Hospital Sydney Limited (“St. Vincent’s”) under the Company’s amended and restated license agreement with St. Vincent’s. In addition, royalties on approved products will be payable to St. Vincent’s, and the Company and Novartis will share that obligation equally. Novartis has responsibility under the license agreement for the development, manufacture and commercialization of the Company’s antibodies and any resulting approved therapeutic products. The Company has agreed that it will not directly or indirectly develop, manufacture or commercialize any GDF15 modulator as a human therapeutic during the term of the license agreement. Activities under the agreement with Novartis were evaluated under ASC 605-25 to determine whether such activities represented a multiple element revenue arrangement. The agreement with Novartis includes the following non-contingent deliverables: (i) the Company’s grant of an exclusive, worldwide license to develop and commercialize the Product; (ii) the Company’s obligation to transfer all technical knowledge and data useful in the development and manufacture of the Product; and (iii) the Company’s obligation to cooperate with Novartis’ requests for transition assistance during a 90-day period. The Company determined that the option to purchase the Company’s existing inventory was a contingent deliverable. The Company determined the delivered license and obligation to transfer technical knowledge and data have standalone value from the undelivered cooperation. The Company allocated upfront consideration of $15.0 million to the delivered license and technical knowledge and recognized this amount as revenue during the year ended December 31, 2015. The relative selling price of the undelivered cooperation had de minimis The Company received a cash payment of $3.5 million related to the delivery of its inventory of clinical quality drug substance to Novartis during the three months ended March 31, 2016. No milestone payments have been earned as of December 31, 2016. Pharmstandard In August 2015, the Company entered into a license agreement with JSC “Pharmstandard-Ufimskiy Vitamin Plant,” a company registered under the laws of the Russian Federation (“Pharmstandard”). Pharmstandard is a subsidiary of Pharmstandard OJSC. Under the license agreement, the Company granted to Pharmstandard the exclusive, sublicensable right to develop, manufacture and commercialize tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (the “Pharmstandard Licensed Territories”) for all diseases and conditions in humans, excluding non-oncologic ocular conditions. In June 2016, following unsuccessful efforts to renegotiate certain terms of the Pharmstandard license agreement, Pharmstandard notified the Company that due to economic and market changes in Russia it was exercising its right to terminate the license agreement effective September 9, 2016. Upon termination of the license agreement, the licenses to tivozanib granted to Pharmstandard were terminated, all product rights and regulatory documents were transferred to the Company and Pharmstandard is no longer responsible for the development and commercialization of tivozanib in the Pharmstandard Licensed Territories. Pharmstandard filed an application for marketing authorization in Russia for tivozanib for the treatment of renal cell carcinoma that was accepted by the Ministry of Health of the Russian Federation in February 2016. This application was withdrawn following Pharmstandard’s termination notice. Activities under the agreement with Pharmstandard were evaluated under ASC 605-25 to determine whether such activities represented a multiple element revenue arrangement. The agreement with Pharmstandard included the following non-contingent deliverables: (i) the Company’s grant of an exclusive license to develop and commercialize tivozanib in the , upon request, to all clinical data, regulatory filings, safety data and manufacturing data to Pharmstandard for use in the development and commercialization of tivozanib in the Pharmstandard Licensed Territories The Company determined the delivered license did not have standalone value from the undelivered items and that the arrangement should be treated as a single unit of accounting. The Company allocated the upfront payment of $1.0 million to the bundled unit of accounting and was recognizing it over the Company’s performance period through April 2022, the remaining patent life of tivozanib. Upon the effective date of the termination, the remaining deferred revenue of approximately $0.9 million was recognized. and $61 thousand Ophthotech In November 2014 the Company entered into a research and exclusive option agreement (the “Option Agreement”), with Ophthotech Corporation (“Ophthotech”) pursuant to which the Company provided Ophthotech an exclusive option to enter into a definitive license agreement whereby the Company would grant Ophthotech the right to develop and commercialize tivozanib outside of Asia and the Middle East for the potential diagnosis, prevention and treatment of non-oncologic diseases or conditions of the eye in humans. Pursuant to this Option Agreement, the Company granted to Ophthotech an exclusive, royalty-free license or sublicense, as applicable, under intellectual property rights controlled by the Company solely to perform the research and development activities related to the use of tivozanib for the specific purposes outlined in the agreement during the option period. These activities included formulation work for ocular administration, preclinical research and the conduct of a phase 1/2a proof-of-concept clinical trial of a product containing tivozanib in patients with wet age-related macular degeneration (the “POC Study”). Ophthotech paid the Company $0.5 million in consideration for the grant of the option. Such amount is non-refundable and not creditable against any other amounts due under the agreement. Under the Option Agreement, the Company was entitled to receive, among other potential payments, a one-time milestone payment of $6.0 million on December 31, 2016; provided, however, that the milestone payment would not be payable if Ophthotech gave the Company a notice of termination of the Option Agreement within thirty (30) days after December 31, 2016. In January 2017, Ophthotech formally notified it is not going to be develop and is exercising its right to terminate effective April , 2017. Activities under the agreement with Ophthotech were evaluated under ASC 605-25 to determine whether such activities represented a multiple element revenue arrangement. The agreement with Ophthotech includes the following non-contingent deliverables: (i) the Company’s obligation to grant an exclusive option to Ophthotech to enter into a license agreement to develop and commercialize products incorporating tivozanib for treatment of diseases or conditions of the eye outside of Asia and the Middle East during the option period (the “Option Grant Deliverable”); (ii) the Company’s obligation to enter into an amendment with KHK to modify the terms of the existing KHK license agreement to negotiate a mutually acceptable form of license agreement; and (iii) the Company’s obligation to transfer research-grade tivozanib drug substance for Ophthotech to conduct the option period research. The Company determined that the delivered Option Grant Deliverable did not have standalone value from the remaining deliverables since Ophthotech could not obtain the intended benefit of the option without the remaining deliverables. Similarly, the remaining deliverables have no standalone value without the Option Grant Deliverable. The Company is accounting for the deliverables as one unit of accounting. Under the Option Agreement, the Company received a cash payment of $0.5 million during the year ended December 31, 2014. The Company deferred the payment and is recording the deferred revenue over the Company’s period of performance, which is currently estimated to be through December 2017. The Company recorded approximately $0.1 million, $0.2 million and $38 thousand of revenue during the years ended December 31, 2016, 2015 and 2014, respectively. Upon the effective date of the termination, the remaining deferred revenue of approximately $0.1 million will be recognized. Biodesix In April 2014, the Company entered into a worldwide co-development and collaboration agreement with Biodesix (the “Biodesix Agreement”) to develop and commercialize ficlatuzumab, the Company’s HGF inhibitory antibody. Under the Biodesix Agreement, the Company granted Biodesix perpetual, non-exclusive rights to certain intellectual property, including all clinical and biomarker data related to ficlatuzumab, to develop and commercialize VeriStrat ® ® Under the Biodesix Agreement, with the exception of the costs incurred for the FOCAL trial, the Company and Biodesix are each required to contribute 50% of all clinical, regulatory, manufacturing and other costs to develop ficlatuzumab. Pursuant to the Biodesix Agreement, Biodesix was obligated to fund all costs of the FOCAL trial up to a cap of $15 million, following which all costs of the FOCAL trial would be shared equally. In connection with the discontinuation of the FOCAL trial, on October 14, 2016 the Company and Biodesix amended the Biodesix Agreement. Under the amendment, the Company agreed to share 50% of the cost of the FOCAL trial from August 1, 2016 through its closeout. In return for bearing 50% of the FOCAL costs after August 1, 2016, the Company will be entitled to recover an agreed multiple of the additional costs borne by the Company out of any income Biodesix receives from the partnership in connection with the licensing or commercialization of ficlatuzumab. Following such recovery, the payment structure under the original Biodesix Agreement, which generally provides that the parties share equally in any costs and revenue, will resume without such modification. Pending marketing approval or the sublicense of ficlatuzumab, and subject to the negotiation of a commercialization agreement, each party would share equally in commercialization profits and losses, subject to the Company’s right to be the lead commercialization party. Prior to the first commercial sale of ficlatuzumab, each party has the right to elect to discontinue participating in further development or commercialization efforts with respect to ficlatuzumab, which is referred to as an “Opt-Out”. If either AVEO or Biodesix elects to Opt-Out, with such party referred to as the “Opting-Out Party”, then the Opting-Out Party shall not be responsible for any future costs associated with developing and commercializing ficlatuzumab other than any ongoing clinical trials. If AVEO elects to Opt-Out, it will continue to make the existing supply of ficlatuzumab available to Biodesix for the purposes of enabling Biodesix to complete the development of ficlatuzumab, and Biodesix will have the right to commercialize ficlatuzumab. After election of an Opt-Out, the non-opting out party shall have sole decision-making authority with respect to further development and commercialization of ficlatuzumab. Additionally, the Opting-Out Party shall be entitled to receive, if ficlatuzumab is successfully developed and commercialized, a royalty equal to 10% of net sales of ficlatuzumab throughout the world, if any, subject to offsets under certain circumstances. Prior to any Opt-Out, the parties shall share equally in any payments received from a third party licensee; provided, however, after any Opt-Out, the Opting-Out Party shall be entitled to receive only a reduced portion of such third-party payments. The agreement will remain in effect until the expiration of all payment obligations between the parties related to development and commercialization of ficlatuzumab, unless earlier terminated. Activities under the Biodesix Agreement were evaluated under ASC 605-25 to determine whether such activities represented a multiple element revenue arrangement. The Biodesix Agreement includes the following non-contingent deliverables: (i) the Company’s obligation to deliver perpetual, non-exclusive rights to certain intellectual property including clinical and biomarker data related to ficlatuzumab for use in developing and commercializing VeriStrat; (ii) the Company’s obligation to participate in the joint steering committee; and (iii) the Company’s obligation to provide its existing supply of ficlatuzumab for development purposes. The Company concluded that any deliverables that would be delivered after the FOCAL trial is complete were contingent deliverables because these services are contingent upon the results of the FOCAL trial. As these deliverables were contingent, and are not at an incremental discount, they are not evaluated as deliverables at the inception of the arrangement. These contingent deliverables will be evaluated and accounted for separately as each related contingency is resolved. As of December 31, 2016, no contingent deliverables had been provided by the Company. The Company determined that the perpetual, non-exclusive rights to certain intellectual property for use in developing and commercializing VeriStrat did not have standalone value from the remaining deliverables since Biodesix could not obtain the intended benefit of the license without the remaining deliverables. Since the remaining deliverables will be performed over the same period of performance, there is no difference in accounting for the deliverables as one unit or multiple units of accounting, and therefore, the Company is accounting for the deliverables as one unit of accounting. The Company records the consideration earned in connection with the FOCAL trial, which consists of reimbursements from Biodesix for expenses related to the trial, as a reduction to research and development expense during the period that reimbursable expenses are incurred. As a result of the cost sharing provisions in the Biodesix Agreement, the Company reduced research and development expenses by approximately $2.5 million, $3.5 million and $2.7 million during the years ended December 31, 2016, 2015 and 2014, respectively. The amount due to the Company from Biodesix pursuant to the cost-sharing provision was approximately $0.8 million and $1.1 million at December 31, 2016 and 2015, respectively. Astellas Pharma In February 2011, the Company, together with its wholly-owned subsidiary AVEO Pharma Limited, entered into a collaboration and license agreement (the “Astellas Agreement”) with Astellas Pharma Inc. and certain of its subsidiaries (together, “Astellas”), pursuant to which the Company and Astellas intended to develop and commercialize tivozanib for the treatment of a broad range of cancers. Astellas elected to terminate the agreement effective on August 11, 2014, at which time the tivozanib rights were returned to the Company. In accordance with the Astellas Agreement, committed development costs, including the costs of completing certain tivozanib clinical development activities, continue to be shared equally. The Company accounted for the joint development and commercialization activities in North America and Europe as a joint risk-sharing collaboration in accordance with ASC 808, Collaborative Arrangements Under the agreement, the Company received cash payments related to reimbursable payments and milestone payments of $0.3 million, $1.5 million and $4.1 million during the years ended December 31, 2016, 2015 and 2014, respectively. Biogen Idec International GmbH In March 2009, the Company entered into an exclusive option and license agreement with Biogen regarding the development and commercialization of the Company’s discovery-stage ErbB3-targeted antibodies, AV-203, for the potential treatment and diagnosis of cancer and other diseases outside of North America. Under the agreement, the Company was responsible for developing ErbB3 antibodies through completion of the first phase 2 clinical trial designed in a manner that, if successful, will generate data sufficient to support advancement to a phase 3 clinical trial. In March 2014, the Company and Biogen amended the exclusive option and license agreement (the “Amendment”). Pursuant to the Amendment, Biogen agreed to the termination of its rights and obligations under the agreement, including Biogen’s option to (i) obtain a co-exclusive (with AVEO) worldwide license to develop and manufacture ErbB3 targeted antibodies and (ii) obtain exclusive commercialization rights to ErbB3 products in countries in the world other than North America. As a result, AVEO has worldwide rights to AV-203. Pursuant to the Amendment, the Company was obligated to use reasonable efforts to seek a collaboration partner for the purpose of funding further development and commercialization of ErbB3 targeted antibodies. The Company is also obligated to pay Biogen a percentage of milestone payments received by AVEO from future partnerships after March 28, 2016 and single digit royalty payments on net sales related to the sale of ErbB3 products, if any, up to cumulative maximum amount of $50 million. The Company concluded that the Amendment materially modified the terms of the agreement and, as a result, required the application of ASC 605-25. Based upon the terms of the Amendment, the remaining deliverables included the Company’s obligation to seek a collaboration partner to fund further development of the program and the Company’s obligation to continue development and commercialization of the licensed products if a collaboration partner is secured (“Development Deliverable”). The Company concluded that its obligation to use best efforts to seek a collaboration partner does not have standalone value from the Development Deliverable upon delivery and thus the deliverables should be treated as a single unit of accounting. Upon modifying the arrangement, the Company had $14.7 million of deferred revenue remaining to be amortized. The Company is not entitled to receive any further consideration from Biogen Idec under the agreement, as amended. The Company allocated a portion of the remaining deferred revenue to the undelivered unit of accounting based upon the Company’s best estimate of the selling price, as the Company determined that neither VSOE nor TPE were available. The Company determined the best estimate of selling price to be approximately $0.6 million and recognized the remaining $14.1 million as collaboration revenue in March 2014. The deferred revenue associated with the undelivered unit of accounting was recognized on a straight-line basis over the period of performance, or through March 2016, when the Company executed its agreement with CANbridge. Under the agreement, the Company recorded revenue of $38 thousand, $0.3 million and $14.5 million during the years ended December 31, 2016, 2015 and 2014, respectively. In March 2016, the Company entered into a collaboration and license agreement for AV-203 with CANbridge. See “—CANbridge” herein for a further description of that arrangement. In-License Agreements St. Vincent’s In July 2012, the Company entered into a license agreement with St. Vincent’s, under which the Company obtained an exclusive, worldwide license to research, develop, manufacture and commercialize products for human therapeutic, preventative and palliative applications that benefit from inhibition or decreased expression or activity of MIC-1, which is also referred to as GDF15. Under the agreement, the Company has the right to grant sublicenses subject to certain restrictions. Under the license agreement, St. Vincent’s also granted the Company non-exclusive rights for certain related diagnostic products and research tools. In order to sublicense certain necessary intellectual property rights to Novartis in August 2015, the Company and St. Vincent’s amended and restated the license agreement (the “Amended St. Vincent’s Agreement”). Under the Amended St. Vincent’s Agreement, the Company was required to make an upfront payment to St. Vincent’s of $1.5 million. St. Vincent’s is also eligible to receive up to approximately $18.9 million in connection with development and regulatory milestones and /or defined timelines under the Amended St. Vincent’s Agreement. Royalties for approved products resulting from the Amended St. Vincent’s Agreement will also be payable to St. Vincent’s, and the Company and Novartis will share that obligation equally. Under the license agreement with Novartis, the Company is required to maintain the Amended St. Vincent’s Agreement in effect, and not enter into any amendment that would adversely affect Novartis’ rights during the term of the license agreement with Novartis. During the year ended December 31, 2016, the Company made a $0.4 million milestone payment to St. Vincent’s related to the selection of a development candidate. Kyowa Hakko Kirin (KHK) In December 2006, the Company entered into a license agreement with KHK under which it obtained an exclusive license, with the right to grant sublicenses subject to certain restrictions, to research, develop, manufacture and commercialize tivozanib, pharmaceutical compositions thereof and associated biomarkers. Its exclusive license covers all territories in the world except for Asia and the Middle East, where KHK has retained the rights to tivozanib. Under the license agreement, the Company obtained exclusive rights in its territory under certain KHK patents, patent applications and know-how related to tivozanib, to research, develop, make, have made, use, import, offer for sale, and sell tivozanib for the diagnosis, prevention and treatment of any and all human diseases and conditions. The Company and KHK each have access to and can benefit from the other party’s clinical data and regulatory filings with respect to tivozanib and biomarkers identified in the conduct of activities under the license agreement. Under the license agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize tivozanib in its territory, including meeting certain specified diligence goals. Prior to the first anniversary of the first post-marketing approval sale of tivozanib in its territory, neither the Company nor any of its subsidiaries has the right to conduct certain clinical trials of, seek marketing approval for or commercialize any other cancer product that also works by inhibiting the activity of a VEGF receptor. The Company has upfront, milestone and royalty payment obligations to KHK under the license agreement. Upon entering into the license agreement with KHK, the Company made an upfront payment in the amount o

Other Accrued Liabilities

Other Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Other Accrued Liabilities	(5) Other Accrued Liabilities Other accrued expenses consisted of the following: December 31, 2016 December 31, 2015 (in thousands) Professional fees $ 464 $ 573 Compensation and benefits 891 938 Restructuring — 357 Other 176 272 Total $ 1,531 $ 2,140

Loans Payable

Loans Payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Loans Payable	(6) Loans Payable On May 28, 2010, the Company entered into the Loan Agreement with Hercules . The Loan Agreement was subsequently amended in March 2012 (the “2012 Amendment , September 2014 (the “2014 Amendment May 2016 Pursuant to the 2014 Amendment additional loan proceeds from Hercules amount of $10.0 million and continues to be The 2014 Amendment was Debt—Modifications and Extinguishments . In connection with the 2014 Amendment, the Company issued warrants to the lenders to purchase up to 608,696 shares of the Company’s common stock at an exercise price equal to $1.15 per share. The Company recorded the fair value of the warrants of approximately $0.4 million as stockholders’ equity and as a discount to the related loan outstanding and is amortizing the value of the discount to interest expense over the term of the loan using the effective interest method. As of December 31, 2016, none of these warrants have been exercised. Pursuant to the 2016 the Company received loan from Hercules in the amount of $5.0 million outstanding principal balance $15.0 million. The Company is not required to principal on the $15 million loan until July 1, 2017, at which time the Company will be required to make 30 principal and interest December 2019. An end-of-term payment of approximately $0.2 million is due on December 1, 2019. The Company incurred approximately $0.1 million in loan issuance costs paid directly to Hercules, which were offset against the loan proceeds and are accounted for as a loan discount. The accounted for as a loan modification in accordance with ASC 470-50 . The 2016 a financial covenant that requires the Company to maintain an unrestricted cash position greater than or equal to $10.0 million through the date of completion of the Company’s Phase 3 TIVO-3 trial. Because the Company was in compliance with the financial covenant at December 31, 2016, the Company has classified the outstanding principal in current and long-term liabilities based on the timing of scheduled principal payments. Refer to Note 1 for the potential adverse consequences of not complying with the financial covenant in future periods. Under the 2016 , from March 1, 2017 through June 30, 2017, draw down an additional $5.0 million in funding upon the : (i) achieving developmental progression on a minimum of two (2) clinical programs (other than the Phase 3 TIVO-3 trial) that are either managed directly by the Company or funded, in whole or in part, by the Company and (ii) having an unrestricted cash position greater than or equal to $25.0 million on the date of the draw down request. If the Company draws down the additional $5.0 million in funding, the commencement of principal payments deferred by six months from July 1, 2017 until January 1, 2018. In connection with the 2016 The unamortized discount to be recognized over the remainder of the loan period was approximately $1.0 million and $0.5 million as of December 31, 2016 and December 31, 2015, respectively. The Company must make interest payments on the loan balance each month it remains As part of the Loan Agreement, Hercules also received an option, subject to the Company’s written consent, not to be unreasonably withheld, to purchase, either with cash or through conversion of outstanding principal under the loan, up to $2.0 million of equity of the Company sold in any sale by the Company to third parties of equity securities resulting in at least $10.0 million in net cash proceeds to the Company, subject to certain exceptions. The Company has evaluated the embedded conversion option, and has concluded that it does not need to be bifurcated and separately accounted for. No amount will be recognized for the conversion feature until such time as the conversion feature is exercised and it can be determined whether a beneficial conversion feature exists. In connection with the Company’s May 2016 private placement (refer to Note 7), Hercules purchased 259,067 units for cash proceeds of $0.2 million to the Company. This purchase was separate from the $2.0 million equity purchase option under the Loan Agreement. The loans are secured by a lien on all the Company’s personal property (other than intellectual property), whether owned or acquired after the date of the Loan Agreement. The Loan Agreement defines , the Company was in compliance with all loan covenants The Company has determined that the risk of subjective acceleration under the material adverse events clause is remote and therefore has classified the outstanding principal in current and long-term liabilities based on the timing of scheduled principal payments. Future minimum payments under the loans payable outstanding as of December 31, 2016 are as follows (amounts in thousands): Year Ending December 31: 2017 $ 4,386 2018 7,506 2019 7,159 19,051 Less amount representing interest (3,361 ) Less unamortized discount (997 ) Less deferred charges (690 ) Less loans payable current, net of discount (2,124 ) Loans payable, net of current portion and discount $ 11,879

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Common Stock	(7) Common Stock As of December 31, 2016, the Company had 200,000,000 authorized shares of common stock, $0.001 par value, of which 75,862,946 shares were issued and outstanding. Private Placement / PIPE Warrants In May 2016, the Company entered into a securities purchase agreement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors pursuant to which the Company sold 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17.0 million. Each unit consisted of one share of the Company’s common stock and a warrant to purchase one share of the Company’s common stock (the “PIPE Warrants”). The PIPE Warrants have an exercise price of $1.00 per share and are exercisable for a period of five years from the date of issuance. Certain of the Company’s directors and executive officers purchased an aggregate of 544,039 units in this offering at the same price as the other investors. The net offering proceeds to the Company were approximately $15.4 million after deducting placement agent fees and other offering expenses payable by the Company. The PIPE Warrants contain a provision giving the warrant holder the option to receive cash, equal to the fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity The key assumptions used to value the PIPE Warrants were as follows: Original Issuance December 31, 2016 Expected price volatility 76.25% 78.18% Expected term (in years) 5.00 4.50 Risk-free interest rates 1.22% 1.93% Stock price $ 0.89 $ 0.54 Dividend yield — — ATM Sales Agreement In February 2015, the Company entered into an at-the-market issuance sales agreement (the “Sales Agreement”) with FBR & Co. (formerly MLV & Co. LLC) (“FBR”), pursuant to which the Company could issue and sell shares of its common stock from time to time up to an aggregate amount of $17.9 million, at the Company’s option, through FBR as its sales agent. Sales of common stock through FBR may be made by any method that is deemed an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Subject to the terms and conditions of the Sales Agreement, FBR will use commercially reasonable efforts to sell the common stock based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is not obligated to make any sales of its common stock under the Sales Agreement. Any shares sold will be sold pursuant to an effective shelf registration statement on Form S-3. The Company will pay FBR a commission of up to 3% of the gross proceeds. The Sales Agreement may be terminated by the Company at any time. On May 7, 2015, the Company filed a shelf registration statement on Form S-3 with the SEC, which covers the offering, issuance and sale by the Company of up to $100.0 million of its common stock, preferred stock, debt securities, warrants and/or units (the “2015 Shelf”). The 2015 Shelf was filed to replace the Company’s existing $250.0 million shelf registration statement (the “2012 Shelf”). On May 7, 2015, the Company also amended its Sales Agreement with FBR to provide for the offering, issuance and sale by the Company of up to $15.0 million of its common stock under the 2015 Shelf, which replaced the Company’s existing $17.9 million offering that expired along with the expired 2012 Shelf. As of December 31, 2016, the Company has sold approximately 5.9 million shares pursuant to the Sales Agreement, as amended, resulting in proceeds of approximately $10.2 million, net of commissions and issuance costs. No shares have been sold during the year ended December 31, 2016. Approximately $9.1 million remains available for sale under the Sales Agreement.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	(8) Stock-based Compensation Stock Incentive Plan The Company maintains the 2010 Stock Incentive Plan (the “Plan”) for employees, consultants, advisors, and directors, as amended in March 2013 and June 2014. The Plan provides for the grant of equity awards such as stock options and restricted stock. The Company has reserved 8,500,000 shares of common stock under the Plan. The Plan provides that the exercise price of incentive stock options cannot be less than 100% of the fair market value of the common stock on the date of the award for participants who own less than 10% of the total combined voting power of stock of the Company and not less than 110% for participants who own more than 10% of the total combined voting power of the stock of the Company. Options and restricted stock granted under the Plan vest over periods as determined by the Board, which generally are equal to four years. Options generally expire ten years from the date of grant. As of December 31, 2016, there were 2,746,513 shares available for future issuance under the Plan. The following table summarizes stock option activity during the year ended December 31, 2016: Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2016 4,796,005 $ 3.78 Granted 1,781,134 $ 1.01 Exercised (38,749 ) $ 0.84 Forfeited (1,679,712 ) $ 5.17 Outstanding at December 31, 2016 4,858,678 $ 2.31 7.98 $ — Vested or expected to vest at December 31, 2016 3,043,129 $ 3.04 7.63 $ — Exercisable at December 31, 2016 2,327,806 $ 3.63 7.34 $ — Stock options to purchase 197,650 shares of common stock contain market conditions which were not deemed probable of vesting at December 31, 2016. The fair value of stock options subject only to service or performance conditions that are granted to employees is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions noted in the following table: Years Ended December 31, 2016 2015 2014 Volatility factor 72.18% - 74.47% 73.04% - 78.70% 69.38% - 77.92% Expected term (in years) 3.00 - 6.25 5.50 - 6.25 5.50 - 6.25 Risk-free interest rates 1.07% - 2.01% 1.54% - 1.93% 1.81% - 2.02% Dividend yield — — — The risk-free interest rate is determined based upon the United States Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the options being valued. The Company does not expect to pay dividends in the foreseeable future. In 2016, the Company began calculating volatility using its historical data. Previously, the Company did not have sufficient history to support a calculation of volatility using only its historical data. As such, in 2014 and 2015, the Company used a weighted-average volatility considering the Company’s own volatility since March 2010, and the volatilities of several peer companies. For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, similar vesting terms and in-the-money option status. Due to lack of available option activity data, the Company elected to use the “simplified” method for “plain vanilla” options to estimate the expected term of the stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. Based upon these assumptions, the weighted-average grant date fair value of stock options granted during the years ended December 31, 2016, 2015 and 2014 was $0.65, $0.75 and $1.15, respectively. The Company is required to include an estimate of the value of the awards that will be forfeited in calculating compensation costs, which the Company estimates based upon actual historical forfeitures. The forfeiture estimates are recognized over the requisite service period of the awards on a straight-line basis. The Company estimated its forfeiture rate to be approximately 76%, 71% and 62% during the years ended December 31, 2016, 2015 and 2014, respectively. As of December 31, 2016, there was $0.8 million of total unrecognized stock-based compensation expense related to stock options granted to employees under the Company’s 2002 Stock Incentive Plan and 2010 Stock Incentive Plan (collectively, the “Plans”). The expense is expected to be recognized over a weighted-average period of 2.5 years. The intrinsic value of options exercised during the years ended December 31, 2016 and 2015 was $6,000 and $58,000, respectively. No options were exercised during the year ended December 31, 2014. Stock Incentive Plan—Restricted Stock The Company periodically grants awards of restricted stock to employees. These awards typically vest upon completion of the requisite service period or upon achievement of specified performance targets. The following table summarizes the restricted stock activity during the year ended December 31, 2016: Number of Shares Weighted- Average Fair-Value Unvested at January 1, 2016 42,750 $ 1.61 Granted — — Vested/Released (42,750 ) 1.61 Unvested at December 31, 2016 — — The fair value of restricted stock awards that vested was $0.1 million in each of the years ended December 31, 2016 and 2015, and $0.2 million for the year ended December 31, 2014. Employee Stock Purchase Plan In February 2010, the Board of Directors adopted the 2010 Employee Stock Purchase Plan (the “ESPP”) pursuant to which the Company may sell up to an aggregate of 250,000 shares of Common Stock, as amended in March 2013. The ESPP allows eligible employees to purchase common stock at a price per share equal to 85% of the lower of the fair market value of the common stock at the beginning or end of each six-month period during the term of the ESPP. The Company has reserved 764,000 shares of common stock under the ESPP. As of December 31, 2016, there were 307,282 shares available for future issuance under the ESPP. Pursuant to the ESPP, the Company did not sell any shares of common stock during the year ended December 31, 2016. For the year ended December 31, 2015, the Company sold a total of 7,138 shares of common stock at purchase prices of $0.75 and $1.07, respectively, which represent 85% of the closing price of the Company’s common stock on June 30, 2015 and December 31, 2015, respectively. For the year ended December 31, 2014, the Company sold a total of 139,032 shares of common stock at purchase prices of $1.53 and $0.71, respectively, which represent 85% of the closing price of the Company’s common stock on June 30, 2014 and December 31, 2014, respectively. The total stock-based compensation expense recorded as a result of the ESPP was approximately $2 thousand, $27 thousand and $0.2 million during the years ended December 31, 2016, 2015 and 2014, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	( 9) Commitments and Contingencies Operating Leases The Company leases office and has leased lab space and equipment under various operating lease agreements. Rent expense under the operating leases amounted to $0.6 million, ($9.1) million and $4.1 million for the years ended December 31, 2016, 2015 and 2014, respectively. For the year ended December 31, 2014, $3.1 million of rent expense is included within lease exit costs on the Company’s statement of operations. The net rent credit for the year ended December 31, 2015 was recorded within operating expenses and allocated to research and development and general and administrative expense based upon the use of the underlying facility space. Refer to the following paragraphs and Note 12 for further discussion of the net rent credit recognized in 2015. In May 2015, the Company began leasing office space under a cancellable arrangement. The Company recognized rent expense of approximately $0.2 million related to this lease during the year ended December 31, 2015. On May 9, 2012, the Company entered into a lease agreement with BMR-650 E KENDALL B LLC (“BMR”), under which the Company agreed to lease 126,065 square feet of space located at 650 East Kendall Street, Cambridge, Massachusetts to be used for office, research and laboratory space. The initial term of the lease agreement was approximately twelve years and seven months (the “initial term”). The Company has determined that the lease should be classified as an operating lease. In order to make the space usable for the Company’s operations, substantial improvements were made to the space. These improvements were planned, managed and carried out by the Company and the improvements were tailored to the Company’s needs. BMR agreed to reimburse the Company for up to $14.9 million of the improvements, and the Company bore all risks associated with any cost overruns that may be incurred. As such, the Company determined it was the owner of the improvements and, as such, the Company accounted for tenant improvement reimbursements from BMR as a lease incentive. The Company recorded a deferred lease incentive (included as a component of the deferred rent balance in the accompanying consolidated balance sheets) and the incentive was amortized as an offset to rent expense over the term of the lease. Rent expense, inclusive of the escalating rent payments, was recognized on a straight-line basis over the initial term of the lease agreement. Refer to Note 12 for further discussion regarding the termination of this lease. The Company recognized rent expense of approximately ($9.5) and $4.3 million related to the lease during the years ended December 31, 2015 and 2014, respectively. The expense recognized during the years ended December 31, 2015 and 2014 included the recognition of deferred rent credits totaling $10.6 million and $3.8 million, respectively, following the termination of the lease agreement. Employment Agreements Certain key executives are covered by severance and change in control agreements. Under these agreements, if the executive’s employment is terminated without cause or if the executive terminates his employment for good reason, such executive will be entitled to receive severance equal to his base salary, benefits and prorated bonuses for a period of time equal to either 12 months or 18 months, depending on the terms of such executive’s individual agreement. In addition, in December 2007, the Company approved a key employee change in control severance benefits plan, which was amended in November 2009, and which provides for severance and other benefits under certain qualifying termination events upon a change in control for a period of time ranging from 6 months to 18 months, depending upon the position of the key employee. Refer to Note 15 for further discussion of legal contingencies.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	( 10) Income Taxes The Company accounts for income taxes under the provisions of ASC 740. For the year ended December 31, 2016 the Company recorded a $0.1 million tax provision for foreign withholding taxes in connection with the $1.0 million upfront payment by CANbridge under the collaboration and license agreement entered into in March 2016. For the years ended December 31, 2015 and 2014, the Company did not have any federal, state, or foreign income tax expense as it generated taxable losses in all filing jurisdictions. A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows for the years ended December 31, 2016, 2015 and 2014: Years Ended December 31, 2016 2015 2014 Income tax computed at federal statutory tax rate 34.0% 34.0% 34.0% State taxes, net of federal benefit 5.2% 5.3% 5.3% Research and development credits 1.4% 2.0% 2.6% Other permanent differences 6.1% (2.0)% (0.8)% Foreign rate differential (0.1)% (0.1)% — Foreign withholding taxes (0.4)% — — SEC settlement liability — (9.1)% — Other (6.6)% (3.8)% (5.7)% Change in valuation allowance (39.6)% (26.3)% (35.4)% Total — — — Prior to 2011, the Company had incurred net operating losses from inception. At December 31, 2016, the Company had domestic federal, state, and UK net operating loss carryforwards of approximately $476.2 million, $366.9 million, and $6.7 million respectively, available to reduce future taxable income. The federal net operating loss carryforwards expire beginning in 2024 through 2036 and the state loss carryforwards begin to expire in 2030 and continue through 2036. The foreign net operating loss carryforwards in the UK do not expire. The Company also had federal and state research and development tax credit carryforwards of approximately $10.3 million and $4.2 million, respectively, available to reduce future tax liabilities and which expire at various dates. The federal credits expire beginning in 2023 through 2036 and the state credits expire beginning in 2019 through 2031. The net operating loss and research and development carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may be limited in the event of certain changes in the ownership interest of significant stockholders. The Company’s net deferred tax assets as of December 31, 2016 and 2015 are as follows (in thousands): 2016 2015 NOL carryforwards $ 182,433 $ 170,200 Research and development credits 13,060 12,721 Deferred revenue 867 1,451 Other temporary differences 4,570 5,935 Valuation allowance (200,930) (190,307) Total $ — $ — A full valuation allowance has been recorded in the accompanying consolidated financial statements to offset these deferred tax assets because the future realizability of such assets is uncertain. This determination is based primarily on the Company’s historical losses. Accordingly, future favorable adjustments to the valuation allowance may be required, if and when circumstances change. The valuation allowance increased by $10.6 million, $3.9 million and $18.6 million during the years ended December 31, 2016, 2015, and 2014, respectively, primarily due to the generation of net operating loss carryforwards. As of December 31, 2016, the Company had federal and state net operating losses of approximately $4.1 million related to excess tax deductions that have been excluded from the above table. The benefit of these net operating losses will be recognized as an increase in additional paid in capital when it results in a reduction of taxes payable. The Company applies FASB Interpretation No. 48, “ Accounting for Uncertainty in Income Taxes, an interpretation of FAS 109 Income Taxes The Company may from time to time be assessed interest or penalties by major tax jurisdictions. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. No interest and penalties have been recognized by the Company to date. The Company anticipates that the amount of unrecognized tax benefits recorded will not change in the next twelve months. The following is a reconciliation of the Company’s gross uncertain tax positions at December 31, 2016, 2015 and 2014: Years Ended December 31, 2016 2015 2014 (in thousands) Amount established upon adoption $ 1,200 $ 1,200 $ 1,200 Additions for current year tax provisions — — — Additions for prior year tax provisions — — — Reductions of prior year tax provisions — — — Balance as of end of year $ 1,200 $ 1,200 $ 1,200

Strategic Restructuring

Strategic Restructuring	12 Months Ended
	Dec. 31, 2016
Restructuring And Related Activities [Abstract]
Strategic Restructuring	(11) Strategic Restructuring On January 6, 2015, the Board of the Company approved a strategic restructuring of the Company that eliminated the Company’s internal research function and aligned the Company’s resources with the Company’s future strategic plans. As part of this restructuring, the Company eliminated approximately two-thirds of the Company’s workforce, or 40 positions across the organization. The Company substantially completed the restructuring during the quarter-ended March 31, 2015. The following table summarizes the components of the Company’s restructuring activity recorded in operating expenses and in accrued expenses in the accompanying consolidated balance sheet: Restructuring amounts at December 31, 2015 Restructuring expense incurred during the year ended December 31, 2016 Restructuring amounts paid during the year ended December 31, 2016 Restructuring amounts accrued at December 31, 2016 Employee severance, benefits and related costs. $ 357 — $ (357 ) — Restructuring amounts at December 31, 2014 Restructuring expense incurred during the year ended December 31, 2015 Restructuring amounts paid during the year ended December 31, 2015 Restructuring amounts accrued at December 31, 2015 Employee severance, benefits and related costs. $ — 3,560 $ (3,203 ) $ 357

Facility Lease Exit

Facility Lease Exit	12 Months Ended
	Dec. 31, 2016
Facility Lease Exit [Abstract]
Facility Lease Exit	(12) Facility Lease Exit On May 9, 2012, the Company entered into a lease agreement with BMR-650 E KENDALL B LLC (“BMR”), under which the Company agreed to lease 126,065 square feet of space located at 650 East Kendall Street, Cambridge, Massachusetts to be used for office, research and laboratory space. The initial term of the lease agreement was approximately twelve years and seven months (the “initial term”). The Company had determined that the lease should be classified as an operating lease. In order to make the space usable for the Company’s operations, substantial improvements were made to the space. These improvements were planned, managed and carried out by the Company and the improvements were tailored to the Company’s needs. BMR agreed to reimburse the Company for up to $14.9 million of the improvements, and the Company bore all risks associated with any cost overruns that may be incurred. As such, the Company determined it was the owner of the improvements and, as such, the Company accounted for tenant improvement reimbursements from BMR as a lease incentive. The Company recorded a deferred lease incentive (included as a component of the deferred rent balance in the accompanying consolidated balance sheets) and the incentive was amortized as an offset to rent expense over the term of the lease. Rent expense, inclusive of the escalating rent payments, was recognized on a straight-line basis over the initial term of the lease agreement. In September 2014, the Company entered into the Lease Termination Agreement pursuant to which the Company immediately surrendered leased space at 650 East Kendall Street in Cambridge, Massachusetts that it had previously ceased using earlier in 2014. In connection with the Lease Termination Agreement, the Company agreed to pay the landlord a termination fee totaling $15.6 million. The Company also agreed to surrender its remaining leased space upon 90 days written notice prior to September 24, 2015. In February 2015, the Company provided notice that it would surrender the remaining space on May 29, 2015. Accordingly, the Company revised the estimated useful life of its leasehold improvements related to this office space and amortized such assets through May 2015, resulting in an additional $2.9 million of depreciation expense during the six months ended June 30, 2015. Similarly, the Company accelerated the amortization of its deferred rent and leasehold improvement allowance associated with this office space through May 2015, resulting in an additional $3.5 million of amortization during the six months ended June 30, 2015. The Company recognized rent expense of approximately ($9.5) million and $4.3 million related to the lease during the years ended December 31, 2015 and 2014, respectively. The net rent credit for the year ended December 31, 2015 and December 31, 2014 were recorded within operating expenses and allocated to research and development and general and administrative expense based upon the use of the underlying facility space. The expense recognized during the years ended December 31, 2015 and 2014 include the recognition of deferred rent credits totaling $10.6 million and $3.8 million, respectively, following the termination of the lease agreement. The following table summarizes the components of the Company’s lease exit activity recorded in current liabilities at December 31, 2015: Lease Exit amounts accrued at December 31, 2014 Accretion Expense incurred during the year ended December 31, 2015 Amounts paid during the year ended December 31, 2015 Additional expense incurred during the year ended December 31, 2015 Amounts accrued at December 31, 2015 Lease exit costs $ 4,981 224 $ (5,477 ) $ 272 $ — No costs were incurred during the year ended December 31, 2016.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	( 13) Employee Benefit Plan In 2002, the Company established the AVEO Pharmaceuticals, Inc. 401(k) Plan (the “401(k) Plan”) for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company makes matching contributions of 50% of the first 5% of employee contributions. The Company made matching contributions of $0.1 million for each of the years ended December 31, 2016, 2015 and 2014.

Quarterly Results (Unaudited)

Quarterly Results (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results (Unaudited)	( 14) Quarterly Results (Unaudited) Three Month Ended March 31, 2016 June 30, 2016 September 30, 2016 December 31, 2016 (in thousands, expect per share data) (unaudited) Collaboration and licensing revenue $ 1,203 $ 193 $ 992 $ 127 Operating expenses 8,435 7,335 6,585 9,553 Loss from operations (7,232 ) (7,142 ) (5,593 ) (9,426 ) Change in fair value warranty liability — (996 ) 1,178 4,569 Other expense, net (378 ) (468 ) (551 ) (748 ) Net loss $ (7,710 ) $ (8,606 ) $ (4,966 ) $ (5,605 ) Net loss per share $ (0.13 ) $ (0.13 ) $ (0.07 ) $ (0.07 ) Three Month Ended March 31, 2015 June 30, 2015 September 30, 2015 December 31, 2015 (in thousands, expect per share data) (unaudited) Collaboration and licensing revenue $ 134 $ 134 $ 15,158 $ 3,598 Restructuring and lease exit 4,333 25 — — Operating expenses 5,950 4,730 6,691 9,721 (Loss) income from operations (10,149 ) (4,621 ) 8,467 (6,123 ) Other expense, net (725 ) (835 ) (553 ) (462 ) Net (loss) income $ (10,874 ) $ (5,456 ) $ 7,914 $ (6,585 ) Net (loss) income per share $ (0.21 ) $ (0.10 ) $ 0.14 $ (0.11 )

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	(15) Legal Proceedings Two class action lawsuits have been filed against the Company and certain of the Company’s former officers and directors, (Tuan Ha-Ngoc, David N. Johnston, William Slichenmyer and Ronald DePinho), in the United States District Court for the District of Massachusetts, one captioned Paul Sanders v. Aveo Pharmaceuticals, Inc., et al., No. 1:13-cv-11157-JLT, filed on May 9, 2013, and the other captioned Christine Krause v. AVEO Pharmaceuticals, Inc., et al., No. 1:13-cv-11320-JLT, filed on May 31, 2013. On December 4, 2013, the District Court consolidated the complaints as In re AVEO Pharmaceuticals, Inc. Securities Litigation et al. On April 4, 2014, Karen J. van Ingen, a purported purchaser of AVEO stock, filed a derivative complaint allegedly on behalf of AVEO in the United States District Court for the District of Massachusetts (the “Court”), Civil Action No. 1:14-cv-11672-DJC, naming AVEO, as a nominal defendant and also naming as defendants present and former members of our board of directors, including Tuan Ha-Ngoc, Henri A. Termeer, Kenneth M. Bate, Anthony B. Evnin, Robert Epstein, Raju Kucherlapati, Robert C. Young, and Kenneth E. Weg. The complaint alleged breach of fiduciary duty and abuse of control between January 2012 and May 2013 with respect to allegedly misleading statements and omissions regarding tivozanib. The lawsuit seeks, among other relief, unspecified damages, costs and expenses, including attorneys’ fees, an order requiring us to implement certain corporate governance reforms, restitution from the defendants and such other relief as the court might find just and proper. The Company filed a motion to dismiss the derivative complaint, and after briefing and oral argument, on March 18, 2015 the Court ruled in its favor and dismissed the case with prejudice. The plaintiff then filed a motion seeking to vacate the Court’s order of dismissal and permit filing of an amended complaint, which the Company opposed, and which the Court denied on June 30, 2015. The plaintiff has appealed the Court’s decision to the United States Court of Appeals for the First Circuit. The parties have reached an agreement in principle to settle this matter. The settlement involves certain corporate governance changes and other non-monetary relief. The plaintiff is seeking an award of attorney’s fees, costs, and expenses in the amount of $822,116, as well as an incentive award of $2,500, both of which the Company expects will be paid by insurance in the amount ordered by the Court. On September 16, 2016, the Court granted preliminary approval to the proposed settlement. On December 19, 2016, the Court held a final settlement hearing on the terms of the proposed settlement and to consider the award of fees to the plaintiff’s attorneys. No objections to the settlement were filed with the Court or raised at the hearing. At the hearing, the Court indicated orally that the settlement will be approved, and heard argument regarding the size of plaintiff’s potential attorney’s fee award. A formal approval order has not yet entered and the Court has not ruled on the final amount of fees for the plaintiff’s attorneys (which, as stated above, are expected to be paid by insurance). Until a formal approval order has been entered, there can be no complete assurance that the Court will approve the settlement. On July 3, 2013, the staff (the “SEC Staff”) of the United States Securities and Exchange Commission (the “Commission”) served a subpoena on the Company for documents and information concerning tivozanib, including related communications with the FDA, investors and others. In September 2015, the SEC Staff invited the Company to discuss the settlement of potential claims asserting that the Company violated federal securities laws by omitting to disclose to investors the recommendation by the staff of the FDA on May 11, 2012, that the Company conduct an additional clinical trial with respect to tivozanib. On March 29, 2016, the Commission filed a complaint against the Company and three of its former officers in the U.S. District Court for the District of Massachusetts alleging that the Company misled investors about its efforts to obtain FDA approval for tivozanib. Without admitting or denying the allegations in the Commission’s complaint, the Company consented to the entry of a final judgment pursuant to which the Company paid the Commission a $4.0 million civil penalty to settle the Commission’s claims against it. On March 31, 2016, the District Court entered a final judgment which (i) approved the settlement; (ii) permanently enjoined the Company from violating Section 17(a) of the Securities Act of 1933, as amended, Sections 10(b) and 13(a) of the Securities Exchange Act of 1934, as amended, and rules 10b-5, 12b-20, 13a-1, 13a-11 and 13a-13 promulgated thereunder; and (iii) ordered the Company to pay the agreed-to civil penalty. The Commission’s action against the Company’s three former officers is still pending. The Company is not a party to any litigation or discussions between the SEC Staff and the former officers, and the Company can make no assurance regarding the outcome of that action or the Commission’s claims against those individuals.

Significant Accounting Polici24

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company’s revenues are generated primarily through collaborative research, development and commercialization agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses, or options to obtain licenses, to the Company’s technology, (ii) research and development activities to be performed on behalf of the collaborative partner, and (iii) in certain cases, services in connection with the manufacturing of pre-clinical and clinical material. Payments to the Company under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; milestone payments; and royalties on future product sales. When evaluating multiple element arrangements, the Company considers whether the deliverables under the arrangement represent separate units of accounting. This evaluation requires subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separable from the other aspects of the contractual relationship. In determining the units of accounting, management evaluates certain criteria, including whether the deliverables have standalone value, based on the relevant facts and circumstances for each arrangement. The consideration received is allocated among the separate units of accounting using the relative selling price method, and the applicable revenue recognition criteria are applied to each of the separate units. The Company determines the estimated selling price for deliverables within each agreement using vendor-specific objective evidence (“VSOE”) of selling price, if available, third-party evidence (“TPE”) of selling price if VSOE is not available, or best estimate of selling price if neither VSOE nor TPE is available. Determining the best estimate of selling price for a deliverable requires significant judgment. The Company typically uses best estimate of selling price to estimate the selling price for licenses to the Company’s proprietary technology, since the Company often does not have VSOE or TPE of selling price for these deliverables. In those circumstances where the Company utilizes best estimate of selling price to determine the estimated selling price of a license to the Company’s proprietary technology, the Company considers market conditions as well as entity-specific factors, including those factors contemplated in negotiating the agreements and internally developed models that include assumptions related to the market opportunity, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the Company’s best estimate of selling price, the Company evaluates whether changes in the key assumptions used to determine the best estimate of selling price will have a significant effect on the allocation of arrangement consideration among multiple deliverables. The Company typically receives non-refundable, upfront payments when licensing its intellectual property in conjunction with a research and development agreement. When management believes the license to its intellectual property does not have stand-alone value from the other deliverables to be provided in the arrangement, the Company generally recognizes revenue attributed to the license on a straight-line basis over the Company’s contractual or estimated performance period, which is typically the term of the Company’s research and development obligations. If management cannot reasonably estimate when the Company’s performance obligation ends, then revenue is deferred until management can reasonably estimate when the performance obligation ends. When management believes the license to its intellectual property has stand-alone value, the Company generally recognizes revenue attributed to the license upon delivery. The periods over which revenue should be recognized are subject to estimates by management and may change over the course of the research and development agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Payments or reimbursements resulting from the Company’s research and development efforts for those arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis so long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is reasonably assured. Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance, and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. The Company aggregates its milestones into four categories: (i) clinical and development milestones, (ii) regulatory milestones, (iii) commercial milestones, and (iv) patent-related milestones. Clinical and development milestones are typically achieved when a product candidate advances into a defined phase of clinical research or completes such phase. For example, a milestone payment may be due to the Company upon the initiation of a phase 3 clinical trial for a new indication, which is the last phase of clinical development and could eventually contribute to marketing approval by the FDA or other global regulatory authorities. Regulatory milestones are typically achieved upon acceptance of the submission for marketing approval of a product candidate or upon approval to market the product candidate by the FDA or other global regulatory authorities. For example, a milestone payment may be due to the Company upon the FDA’s acceptance of a New Drug Application (“NDA”). Commercial milestones are typically achieved when an approved pharmaceutical product reaches certain defined levels of net sales by the licensee, such as when a product first achieves global sales or annual sales of a specified amount. Patent-related milestones are typically achieved when a patent application is filed or a patent is issued with respect to certain intellectual property related to the applicable collaboration. Revenues from clinical and development, regulatory, and patent-related milestone payments, if the milestones are deemed substantive and the milestone payments are nonrefundable, are recognized upon successful accomplishment of the milestones. The Company has concluded that the clinical and development, regulatory and patent-related milestones pursuant to its current research and development arrangements are substantive. Milestones that are not considered substantive are accounted for as license payments and recognized on a straight-line basis over the remaining period of performance. Revenues from commercial milestone payments are accounted for as royalties and are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met.
Research and Development Expenses	Research and Development Expenses Research and development expenses are charged to expense as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including internal costs for salaries, bonuses, benefits, stock-based compensation, facilities, and research-related overhead, and external costs for clinical trials, drug manufacturing and distribution, license fees, consultants and other contracted services.
Warrants Issued in Connection with Private Placement	Warrants Issued in Connection with Private Placement In May 2016, the Company issued warrants to purchase an aggregate of 17,642,482 shares of common stock in connection with a private placement financing and recorded the warrants as a liability. The Company accounts for warrant instruments that either conditionally or unconditionally obligate the issuer to transfer assets as liabilities regardless of the timing of the redemption feature or price, even though the underlying shares may be classified as permanent or temporary equity. . These warrants are subject to revaluation at each balance sheet date, and any changes in fair value are recorded as a non-cash component of other income (expense), net until the earlier of their exercise or expiration or upon the completion of a liquidation event. The following table rolls forward the fair value of the Company’s warrant liability, the fair value of which is determined by Level 3 inputs for the year ended December 31, 2016 (in thousands): Fair value at January 1, 2016 $ — Issuance of warrants on May 13, 2016 9,344 Change in fair value (4,751 ) Fair value at December 31, 2016 $ 4,593
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase and an investment in a U.S. government money market fund to be cash equivalents. Changes in the balance of cash and cash equivalents may be affected by changes in investment portfolio maturities, as well as actual cash disbursements to fund operations. The Company’s cash is deposited in highly-rated financial institutions in the United States. The Company invests in high-grade, short-term corporate bonds and other U.S. government agency securities, which management believes are subject to minimal credit and market risk.
Marketable Securities	Marketable Securities Marketable securities consist primarily of investments which have expected average maturity dates in excess of three months, but not longer than 24 months. The Company invests in high-grade corporate obligations, including commercial paper, and U. S. government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations they are classified as current assets on the consolidated balance sheets. Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. The cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, with such amortization and accretion recorded as a component of interest expense, net. Unrealized gains and losses are included in other comprehensive loss until realized, at which point they would be recorded as a component of interest expense, net. Below is a summary of cash, cash equivalents and marketable securities at December 31, 2016 and December 31, 2015: Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2016 Cash and cash equivalents: Cash and money market funds $ 14,091 $ — $ — $ 14,091 Corporate debt securities 1,005 — — 1,005 Total cash and cash equivalents 15,096 — — 15,096 Marketable securities: Corporate debt securities due within 1 year 8,246 6 — 8,252 Total marketable securities 8,246 6 — 8,252 Total cash, cash equivalents and marketable securities $ 23,342 $ 6 $ — $ 23,348 December 31, 2015: Cash and cash equivalents: Cash and money market funds $ 21,822 $ — $ — $ 21,822 Corporate debt securities 4,812 — — 4,812 Total cash and cash equivalents 26,634 — — 26,634 Marketable securities: Corporate debt securities due within 1 year $ 6,504 $ — $ (3 ) $ 6,501 Government agency securities due within 1 year 1,000 — — 1,000 Total marketable securities 7,504 — (3 ) 7,501 Total cash, cash equivalents and marketable securities $ 34,138 $ — $ (3 ) $ 34,135
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in highly-rated federally-insured financial institutions in excess of federally insured limits. The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the high credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. The Company’s accounts receivable primarily consists of amounts due to the Company from licensees and collaborators. As of December 31, 2016, the Company had approximately $1.0 million of accounts receivable outstanding, of which approximately $0.8 million was due from Biodesix pursuant to the Company’s collaboration arrangement for ficlatuzumab (refer to Note 4). The Company has not experienced any material losses related to accounts receivable from individual licensees or collaborators.
Fair Value Measurements	Fair Value Measurements The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. As of December 31, 2016, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a U.S. government money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the year ended December 31, 2016, the Company did not have any transfers of financial assets between Levels 1 and 2. As of December 31, 2016, the Company’s financial liabilities that were recorded at fair value consisted of a warrant liability. The fair value of the Company’s loans payable at December 31, 2016 approximates its carrying value, computed pursuant to a discounted cash flow technique using a market interest rate and is considered a Level 3 fair value measurement. The effective interest rate, which reflects the current market rate, considers the fair value of the warrants issued in connection with the loan, loan issuance costs and the deferred financing charge. The following table summarizes the assets and liabilities measured at fair value on a recurring basis at December 31, 2016 and December 31, 2015: Fair Value Measurements as of December 31, 2016 Level 1 Level 2 Level 3 Total (in thousands) Financial assets carried at fair value: Cash and money market funds $ 14,091 $ — $ — $ 14,091 Corporate debt securities — 1,005 — 1,005 Total cash and cash equivalents $ 14,091 $ 1,005 $ — $ 15,096 Marketable securities: Corporate debt securities due within 1 year — $ 8,252 — $ 8,252 Total marketable securities $ — $ 8,252 $ — $ 8,252 Total cash, cash equivalents and marketable securities $ 14,091 $ 9,257 $ — $ 23,348 Financial liabilities carried at fair value: Warrant liability $ — $ — $ 4,593 $ 4,593 Total warrant liability $ — $ — $ 4,593 $ 4,593 Fair Value Measurements as of December 31, 2015 Level 1 Level 2 Level 3 Total (in thousands) Financial assets carried at fair value: Cash and money market funds $ 21,822 $ — $ — $ 21,822 Corporate debt securities — 4,812 4,812 Total cash and cash equivalents $ 21,822 $ 4,812 $ — $ 26,634 Marketable securities: Corporate debt securities due within 1 year $ — $ 6,501 $ — $ 6,501 Government agency securities due within 1 year — 1,000 — 1,000 Total marketable securities $ — $ 7,501 $ — $ 7,501 Total cash, cash equivalents and marketable securities $ 21,822 $ 12,313 $ — $ 34,135
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repair costs are charged to expense as incurred. Depreciation expense for the years ended December 31, 2016, 2015 and 2014 was $30 thousand, $9.6 million and $6.2 million, respectively. In September 2014, the Company entered into a Lease Termination Agreement (refer to Note 12). As a result, the Company revised the estimated useful life of its leasehold improvements related to this space, resulting in an increase in depreciation expense of approximately $2.4 million during the year ended December 31, 2014. In February 2015, the Company provided notice that it would surrender the remaining space on May 29, 2015. Accordingly, the Company again revised the estimated useful life of its leasehold improvements related to this office space and amortized such assets through May 2015, resulting in an additional $2.9 million of depreciation expense during the year ended December 31, 2015.
Long-lived Assets	Long-lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. The Company recognized $0, $0.2 million and $7.6 million of impairment losses during the years ended December 31, 2016, 2015 and 2014, respectively, primarily related to leasehold improvements.
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the years ended December 31, 2016, 2015 and 2014, diluted net loss per share is the same as basic net loss per share as the inclusion of weighted average shares of unvested restricted common stock and common stock issuable upon the exercise of stock options and warrants would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive for the years ended December 31, 2016, 2015 and 2014, respectively: Years Ended December 31, 2016 2015 2014 Outstanding stock options 4,858,678 4,796,005 5,817,313 Outstanding warrants 19,453,295 608,696 608,696 Unvested restricted stock — 42,750 477,600 Total 24,311,973 5,447,451 6,903,609
Stock-Based Compensation	Stock-Based Compensation Under the Company’s stock-based compensation programs, the Company periodically grants stock options and restricted stock to employees, directors and nonemployee consultants. The Company also issues shares under an employee stock purchase plan. The fair value of all awards is recognized in the Company’s statements of operations over the requisite service period for each award. Awards that vest as the recipient provides service are expensed on a straight-line basis over the requisite service period. Other awards, such as performance-based awards that vest upon the achievement of specified goals, are expensed using the accelerated attribution method if achievement of the specified goals is considered probable. The Company has also granted awards that vest upon the achievement of market conditions. Per Accounting Standards Codification (“ASC”) 718 Share-Based Payments, The Company uses the Black-Scholes option pricing model to value its stock option awards without market conditions, which require the Company to make certain assumptions regarding the expected volatility its common stock price, the expected term of the option grants, the risk-free interest rate and the dividend yield with respect to its common stock. In 2016, the Company began calculating volatility using its historical data. Previously, the Company did not have sufficient history to support a calculation of volatility using only its historical data. As such, prior to 2016, the Company used a weighted-average volatility considering the Company’s own volatility since March 2010 and the volatilities of several peer companies. For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, similar vesting terms and in-the-money option status. Due to the lack of the Company’s own historical data, the Company elected to use the “simplified” method for “plain vanilla” options to estimate the expected term of the Company’s stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate used for each grant is based on the U.S. Treasury yield curve in effect at the time of grant for instruments with a similar expected life. The Company utilizes a dividend yield of zero based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. The fair value of equity-classified awards to employees and directors are measured at fair value on the date the awards are granted. Awards to nonemployee consultants are recorded at their fair values and are re-measured as of each balance sheet date until the recipient’s services are complete. During the years ended December 31, 2016, 2015 and 2014, the Company recorded the following stock-based compensation expense: Years Ended December 31, 2016 2015 2014 (in thousands) Research and development $ 293 $ 298 $ 899 General and administrative 706 765 1,909 Restructuring — 69 — Total stock-based compensation expense $ 999 $ 1,132 $ 2,808 Stock-based compensation expense is allocated to research and development and general and administrative expense based upon the department of the employee to whom each award was granted. Expenses recognized in connection with the modification of awards in connection with the Company’s strategic restructurings are allocated to restructuring expense. No related tax benefits of the stock-based compensation expense have been recognized.
Income Taxes	Income Taxes The Company provides for income taxes using the asset-liability method. Under this method, deferred tax assets and liabilities are recognized based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company calculates its provision for income taxes on ordinary income based on its projected annual tax rate for the year. Uncertain tax positions are recognized if the position is more-likely-than-not to be sustained upon examination by a tax authority. Unrecognized tax benefits represent tax positions for which reserves have been established.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment principally in the United States. As of December 31, 2016 and 2015, the Company has $0.8 million and $1.0 million, respectively, of net assets located in the United Kingdom.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the , and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include revenue recognition, contract research accruals, measurement of the warrant liability and measurement of stock-based compensation. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In March 2016, the FASB issued ASU No. 2016-09, Compensation─Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting

Significant Accounting Polici25

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Fair Value of Company's Warrant Liability	The following table rolls forward the fair value of the Company’s warrant liability, the fair value of which is determined by Level 3 inputs for the year ended December 31, 2016 (in thousands): Fair value at January 1, 2016 $ — Issuance of warrants on May 13, 2016 9,344 Change in fair value (4,751 ) Fair value at December 31, 2016 $ 4,593
Summary of Cash, Cash Equivalents and Marketable Securities	Below is a summary of cash, cash equivalents and marketable securities at December 31, 2016 and December 31, 2015: Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2016 Cash and cash equivalents: Cash and money market funds $ 14,091 $ — $ — $ 14,091 Corporate debt securities 1,005 — — 1,005 Total cash and cash equivalents 15,096 — — 15,096 Marketable securities: Corporate debt securities due within 1 year 8,246 6 — 8,252 Total marketable securities 8,246 6 — 8,252 Total cash, cash equivalents and marketable securities $ 23,342 $ 6 $ — $ 23,348 December 31, 2015: Cash and cash equivalents: Cash and money market funds $ 21,822 $ — $ — $ 21,822 Corporate debt securities 4,812 — — 4,812 Total cash and cash equivalents 26,634 — — 26,634 Marketable securities: Corporate debt securities due within 1 year $ 6,504 $ — $ (3 ) $ 6,501 Government agency securities due within 1 year 1,000 — — 1,000 Total marketable securities 7,504 — (3 ) 7,501 Total cash, cash equivalents and marketable securities $ 34,138 $ — $ (3 ) $ 34,135
Summary of Assets And Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes the assets and liabilities measured at fair value on a recurring basis at December 31, 2016 and December 31, 2015: Fair Value Measurements as of December 31, 2016 Level 1 Level 2 Level 3 Total (in thousands) Financial assets carried at fair value: Cash and money market funds $ 14,091 $ — $ — $ 14,091 Corporate debt securities — 1,005 — 1,005 Total cash and cash equivalents $ 14,091 $ 1,005 $ — $ 15,096 Marketable securities: Corporate debt securities due within 1 year — $ 8,252 — $ 8,252 Total marketable securities $ — $ 8,252 $ — $ 8,252 Total cash, cash equivalents and marketable securities $ 14,091 $ 9,257 $ — $ 23,348 Financial liabilities carried at fair value: Warrant liability $ — $ — $ 4,593 $ 4,593 Total warrant liability $ — $ — $ 4,593 $ 4,593 Fair Value Measurements as of December 31, 2015 Level 1 Level 2 Level 3 Total (in thousands) Financial assets carried at fair value: Cash and money market funds $ 21,822 $ — $ — $ 21,822 Corporate debt securities — 4,812 4,812 Total cash and cash equivalents $ 21,822 $ 4,812 $ — $ 26,634 Marketable securities: Corporate debt securities due within 1 year $ — $ 6,501 $ — $ 6,501 Government agency securities due within 1 year — 1,000 — 1,000 Total marketable securities $ — $ 7,501 $ — $ 7,501 Total cash, cash equivalents and marketable securities $ 21,822 $ 12,313 $ — $ 34,135
Summary of Outstanding Securities Not Included in Computation of Diluted Net Loss Per Common Share	The following table summarizes outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive for the years ended December 31, 2016, 2015 and 2014, respectively: Years Ended December 31, 2016 2015 2014 Outstanding stock options 4,858,678 4,796,005 5,817,313 Outstanding warrants 19,453,295 608,696 608,696 Unvested restricted stock — 42,750 477,600 Total 24,311,973 5,447,451 6,903,609
Stock-Based Compensation Expense	During the years ended December 31, 2016, 2015 and 2014, the Company recorded the following stock-based compensation expense: Years Ended December 31, 2016 2015 2014 (in thousands) Research and development $ 293 $ 298 $ 899 General and administrative 706 765 1,909 Restructuring — 69 — Total stock-based compensation expense $ 999 $ 1,132 $ 2,808

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Other Accrued Liabilities	Other accrued expenses consisted of the following: December 31, 2016 December 31, 2015 (in thousands) Professional fees $ 464 $ 573 Compensation and benefits 891 938 Restructuring — 357 Other 176 272 Total $ 1,531 $ 2,140

Loans Payable (Tables)

Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Future Minimum Payments Under Loans Payable	Future minimum payments under the loans payable outstanding as of December 31, 2016 are as follows (amounts in thousands): Year Ending December 31: 2017 $ 4,386 2018 7,506 2019 7,159 19,051 Less amount representing interest (3,361 ) Less unamortized discount (997 ) Less deferred charges (690 ) Less loans payable current, net of discount (2,124 ) Loans payable, net of current portion and discount $ 11,879

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Key Assumptions Used to Value the PIPE Warrants	The key assumptions used to value the PIPE Warrants were as follows: Original Issuance December 31, 2016 Expected price volatility 76.25% 78.18% Expected term (in years) 5.00 4.50 Risk-free interest rates 1.22% 1.93% Stock price $ 0.89 $ 0.54 Dividend yield — —

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Activity	The following table summarizes stock option activity during the year ended December 31, 2016: Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2016 4,796,005 $ 3.78 Granted 1,781,134 $ 1.01 Exercised (38,749 ) $ 0.84 Forfeited (1,679,712 ) $ 5.17 Outstanding at December 31, 2016 4,858,678 $ 2.31 7.98 $ — Vested or expected to vest at December 31, 2016 3,043,129 $ 3.04 7.63 $ — Exercisable at December 31, 2016 2,327,806 $ 3.63 7.34 $ —
Assumptions used in Black-Scholes Pricing Model for New Grants	The fair value of stock options subject only to service or performance conditions that are granted to employees is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions noted in the following table: Years Ended December 31, 2016 2015 2014 Volatility factor 72.18% - 74.47% 73.04% - 78.70% 69.38% - 77.92% Expected term (in years) 3.00 - 6.25 5.50 - 6.25 5.50 - 6.25 Risk-free interest rates 1.07% - 2.01% 1.54% - 1.93% 1.81% - 2.02% Dividend yield — — —
Restricted Stock Activity	The following table summarizes the restricted stock activity during the year ended December 31, 2016: Number of Shares Weighted- Average Fair-Value Unvested at January 1, 2016 42,750 $ 1.61 Granted — — Vested/Released (42,750 ) 1.61 Unvested at December 31, 2016 — —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Reconciliation of Expected Income Tax Benefit	A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows for the years ended December 31, 2016, 2015 and 2014: Years Ended December 31, 2016 2015 2014 Income tax computed at federal statutory tax rate 34.0% 34.0% 34.0% State taxes, net of federal benefit 5.2% 5.3% 5.3% Research and development credits 1.4% 2.0% 2.6% Other permanent differences 6.1% (2.0)% (0.8)% Foreign rate differential (0.1)% (0.1)% — Foreign withholding taxes (0.4)% — — SEC settlement liability — (9.1)% — Other (6.6)% (3.8)% (5.7)% Change in valuation allowance (39.6)% (26.3)% (35.4)% Total — — —
Company Net Deferred Tax Assets	The Company’s net deferred tax assets as of December 31, 2016 and 2015 are as follows (in thousands): 2016 2015 NOL carryforwards $ 182,433 $ 170,200 Research and development credits 13,060 12,721 Deferred revenue 867 1,451 Other temporary differences 4,570 5,935 Valuation allowance (200,930) (190,307) Total $ — $ —
Reconciliation of Gross Uncertain Tax Positions	The following is a reconciliation of the Company’s gross uncertain tax positions at December 31, 2016, 2015 and 2014: Years Ended December 31, 2016 2015 2014 (in thousands) Amount established upon adoption $ 1,200 $ 1,200 $ 1,200 Additions for current year tax provisions — — — Additions for prior year tax provisions — — — Reductions of prior year tax provisions — — — Balance as of end of year $ 1,200 $ 1,200 $ 1,200

Strategic Restructuring (Tables

Strategic Restructuring (Tables)	12 Months Ended
	Dec. 31, 2016
Restructuring And Related Activities [Abstract]
Restructuring Activity Recorded in Operating Expenses and in Accrued Expenses	The following table summarizes the components of the Company’s restructuring activity recorded in operating expenses and in accrued expenses in the accompanying consolidated balance sheet: Restructuring amounts at December 31, 2015 Restructuring expense incurred during the year ended December 31, 2016 Restructuring amounts paid during the year ended December 31, 2016 Restructuring amounts accrued at December 31, 2016 Employee severance, benefits and related costs. $ 357 — $ (357 ) — Restructuring amounts at December 31, 2014 Restructuring expense incurred during the year ended December 31, 2015 Restructuring amounts paid during the year ended December 31, 2015 Restructuring amounts accrued at December 31, 2015 Employee severance, benefits and related costs. $ — 3,560 $ (3,203 ) $ 357

Facility Lease Exit (Tables)

Facility Lease Exit (Tables)	12 Months Ended
	Dec. 31, 2016
Facility Lease Exit [Abstract]
Components of Lease Exit Activity Recorded in Current Liabilities	The following table summarizes the components of the Company’s lease exit activity recorded in current liabilities at December 31, 2015: Lease Exit amounts accrued at December 31, 2014 Accretion Expense incurred during the year ended December 31, 2015 Amounts paid during the year ended December 31, 2015 Additional expense incurred during the year ended December 31, 2015 Amounts accrued at December 31, 2015 Lease exit costs $ 4,981 224 $ (5,477 ) $ 272 $ —

Quarterly Results (Unaudited) (

Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Results	Three Month Ended March 31, 2016 June 30, 2016 September 30, 2016 December 31, 2016 (in thousands, expect per share data) (unaudited) Collaboration and licensing revenue $ 1,203 $ 193 $ 992 $ 127 Operating expenses 8,435 7,335 6,585 9,553 Loss from operations (7,232 ) (7,142 ) (5,593 ) (9,426 ) Change in fair value warranty liability — (996 ) 1,178 4,569 Other expense, net (378 ) (468 ) (551 ) (748 ) Net loss $ (7,710 ) $ (8,606 ) $ (4,966 ) $ (5,605 ) Net loss per share $ (0.13 ) $ (0.13 ) $ (0.07 ) $ (0.07 ) Three Month Ended March 31, 2015 June 30, 2015 September 30, 2015 December 31, 2015 (in thousands, expect per share data) (unaudited) Collaboration and licensing revenue $ 134 $ 134 $ 15,158 $ 3,598 Restructuring and lease exit 4,333 25 — — Operating expenses 5,950 4,730 6,691 9,721 (Loss) income from operations (10,149 ) (4,621 ) 8,467 (6,123 ) Other expense, net (725 ) (835 ) (553 ) (462 ) Net (loss) income $ (10,874 ) $ (5,456 ) $ 7,914 $ (6,585 ) Net (loss) income per share $ (0.21 ) $ (0.10 ) $ 0.14 $ (0.11 )

Organization - Additional Infor

Organization - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)Subsidiary	Dec. 31, 2015USD ($)
Organization [Line Items]
Number of subsidiaries | Subsidiary	2
Cash, cash equivalents and marketable securities	$ 23,300,000
Working capital	16,000,000
Accumulated deficit	(521,916,000)	$ (495,029,000)
Loans Payable | Hercules May 2016 Loan Agreement
Organization [Line Items]
Unrestricted and unencumbered cash and cash equivalents	25,000,000
Loans Payable | Hercules May 2016 Loan Agreement | Financial covenant | Minimum
Organization [Line Items]
Unrestricted and unencumbered cash and cash equivalents	$ 10,000,000

Significant Accounting Polici35

Significant Accounting Policies - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2015USD ($)	Dec. 31, 2016USD ($)Segmentshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)	May 31, 2016shares
Significant Accounting Policies [Line Items]
Common stock, shares issued | shares		75,862,946	58,182,000
Decrease in the fair value of warrant liability		$ 4,800,000
Accounts receivable		1,027,000	$ 4,641,000
Depreciation expense		30,000	9,600,000	$ 6,200,000
Impairment losses		0	200,000	7,600,000
Tax benefits of the stock based compensation expenses recognized		$ 0
Number of operating segments | Segment		1
United Kingdom
Significant Accounting Policies [Line Items]
Net assets located in the United Kingdom		$ 800,000	1,000,000
Leasehold Improvements
Significant Accounting Policies [Line Items]
Depreciation expense				$ 2,400,000
3rd Amendment, Lease exit costs associated with 650 E. Kendall.
Significant Accounting Policies [Line Items]
Leased space surrendering date		May 29, 2015
3rd Amendment, Lease exit costs associated with 650 E. Kendall. | Leasehold Improvements
Significant Accounting Policies [Line Items]
Additional charge to depreciation expense due to revision of estimated useful life	$ 2,900,000		$ 2,900,000
Biodesix
Significant Accounting Policies [Line Items]
Accounts receivable		$ 800,000
Minimum
Significant Accounting Policies [Line Items]
Marketable securities maturity term		3 months
Maximum
Significant Accounting Policies [Line Items]
Marketable securities maturity term		24 months
PIPE Warrants [Member] | Private Placement
Significant Accounting Policies [Line Items]
Common stock, shares issued | shares					17,642,482

Summary of Fair Value of Compan

Summary of Fair Value of Company's Warrant Liability (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Issuance of warrants on May 13, 2016	$ 9,344
Change in fair value	(4,751)
Fair value, end of period	$ 4,593

Summary of Cash Equivalents and

Summary of Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 23,342	$ 34,138
Unrealized Gains	6
Unrealized Losses		(3)
Fair Value	23,348	34,135
Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	1,005	4,812
Fair Value	1,005	4,812
Marketable securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	8,246	7,504
Unrealized Gains	6
Unrealized Losses		(3)
Fair Value	8,252	7,501
Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	14,091	21,822
Fair Value	14,091	21,822
Level 2 | Corporate debt securities | Due within 1 year
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	8,246	6,504
Unrealized Gains	6
Unrealized Losses		(3)
Fair Value	8,252	6,501
Level 2 | Government agency securities | Due within 1 year
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost		1,000
Fair Value		1,000
Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	15,096	26,634
Fair Value	$ 15,096	$ 26,634

Summary of Assets And Liabiliti

Summary of Assets And Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 8,252	$ 7,501
Fair Value Measurements Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	15,096	26,634
Marketable securities	8,252	7,501
Total cash, cash equivalents and marketable securities	23,348	34,135
Warrant liability	4,593
Total warrant liability	4,593
Fair Value Measurements Recurring | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,005	4,812
Fair Value Measurements Recurring | Due within 1 year | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	8,252	6,501
Fair Value Measurements Recurring | Due within 1 year | Government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		1,000
Fair Value Measurements Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	14,091	21,822
Total cash, cash equivalents and marketable securities	14,091	21,822
Fair Value Measurements Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,005	4,812
Marketable securities	8,252	7,501
Total cash, cash equivalents and marketable securities	9,257	12,313
Fair Value Measurements Recurring | Level 2 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,005	4,812
Fair Value Measurements Recurring | Level 2 | Due within 1 year | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	8,252	6,501
Fair Value Measurements Recurring | Level 2 | Due within 1 year | Government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		1,000
Fair Value Measurements Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	4,593
Total warrant liability	4,593
Fair Value Measurements Recurring | Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	14,091	21,822
Fair Value Measurements Recurring | Cash and money market funds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 14,091	$ 21,822

Summary of Outstanding Securiti

Summary of Outstanding Securities Not Included in Computation of Diluted Net Loss Per Common Share (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount, outstanding	24,311,973	5,447,451	6,903,609
Stock Option
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount, outstanding	4,858,678	4,796,005	5,817,313
Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount, outstanding	19,453,295	608,696	608,696
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount, outstanding		42,750	477,600

Stock Based Compensation Expens

Stock Based Compensation Expense for Equity-Classified Awards (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 999	$ 1,132	$ 2,808
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	293	298	899
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 706	765	$ 1,909
Restructuring
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense		$ 69

Collaborations and License Ag41

Collaborations and License Agreements - Additional Information (Detail)

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 30, 2016USD ($)

Sep. 30, 2015USD ($)

Aug. 31, 2015USD ($)

Nov. 30, 2014USD ($)

Mar. 31, 2014USD ($)

Dec. 31, 2012USD ($)

Mar. 31, 2010USD ($)

Dec. 31, 2006USD ($)

Dec. 31, 2016USD ($)

Sep. 30, 2016USD ($)

Jun. 30, 2016USD ($)

Mar. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Sep. 30, 2015USD ($)

Jun. 30, 2015USD ($)

Mar. 31, 2015USD ($)

Dec. 31, 2016USD ($)Indication

Dec. 31, 2015USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2011USD ($)

Oct. 14, 2016

Apr. 30, 2014USD ($)

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaboration revenue

$ 127,000

$ 992,000

$ 193,000

$ 1,203,000

$ 3,598,000

$ 15,158,000

$ 134,000

$ 134,000

$ 2,515,000

$ 19,024,000

$ 18,123,000

Amounts due from pursuant to the cost-sharing provisions

$ 1,027,000

4,641,000

1,027,000

4,641,000

Research and development

23,703,000

12,875,000

38,254,000

Credited against amounts due the Company for tenant improvements

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Development and sales-based milestones payment

22,500,000

Will be paid in nine equal monthly installments

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Development and sales-based milestones payment

5,500,000

Scenario 3

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Development and sales-based milestones payment

4,200,000

Sales Based Milestone Payments

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

0

Other License Agreements

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Research and development

25,000

License payment per product

1,000,000

License expense

$ 0

0

0

Other License Agreements | Maximum

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, royalties payment on net sales

1.50%

1.50%

Other License Agreements | Minimum

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, royalties payment on net sales

0.50%

0.50%

CANbridge

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

License agreement date

Mar. 16, 2016

Collaborations and license agreements, milestone payment received

$ 0

CANbridge | Licensing Agreements

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

$ 1,000,000

1,000,000

Upfront payment, withholding taxes

100,000

Reimbursable amount for manufacturing costs and expenses.

$ 1,000,000

Collaborations and license agreements, time period from first commercial sale of certain product upon which the agreement expires

10 years

Allocation of upfront payment

$ 1,000,000

Collaboration revenue

1,000,000

CANbridge | Licensing Agreements | Sales Based Milestone Payments

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

90,000,000

CANbridge | Licensing Agreements | Development and Regulatory Milestone Events

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

42,000,000

CANbridge | Licensing Agreements | Due Within Twelve Months From Effective Date

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Reimbursable amount for manufacturing costs and expenses.

500,000

CANbridge | Licensing Agreements | Due Within Eighteen Months From Effective Date

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Reimbursable amount for manufacturing costs and expenses.

$ 500,000

EUSA

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

License agreement date

Dec. 21, 2006

Collaborations and license agreements, expected milestone receivable

$ 4,000,000

Research and development funding received

2,500,000

2,500,000

Payments received in connection with indications

$ 2,000,000

Eligible number of indications | Indication

3

Payments received in connection with additional indications

$ 5,000,000

Potential payments received in connection with additional indications

335,000,000

Collaborations and license agreements, milestone payment received

400,000

14,000

EUSA | Utilization of Data Generated by Planned Phase Three Study

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone payment to be received

$ 20,000,000

20,000,000

EUSA | Phase One Combination Study

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone payment to be received

2,000,000

2,000,000

EUSA | Marketing Approval in France, Germany, Italy, Spain and the United Kingdom

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone payment to be received

2,000,000

2,000,000

EUSA | Marketing Approval in Argentina, Australia, Brazil, South Africa and Venezuela

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone payment to be received

2,000,000

2,000,000

Novartis

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

$ 15,000,000

Collaborations and license agreements, milestone payment received

0

Reimbursable inventory

$ 3,500,000

License and service revenue

3,500,000

Novartis | Sales Based Milestone Payments

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

150,000,000

Novartis | Clinical Efficacy Milestone

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

53,000,000

Novartis | Regulatory Milestone Events

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

105,000,000

Novartis | License and Technical Knowledge

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaboration revenue

15,000,000

Pharmstandard

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Allocation of upfront payment

1,000,000

Collaboration revenue

900,000

61,000

Collaborations and license agreements, deferred revenue

900,000

$ 900,000

Ophthotech Corporation

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, written notice period for termination

30 days

Ophthotech Corporation | Option and License Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, expected milestone receivable

$ 6,000,000

Upfront license payment

$ 500,000

Collaborations and license agreements, payment received

500,000

Collaborations and license agreements, revenue recognized

100,000

200,000

38,000

Remaining deferred revenue to be recognized

100,000

Biodesix

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Amounts due from pursuant to the cost-sharing provisions

800,000

800,000

Biodesix | FOCAL study

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Contribution percentage of clinical, regulatory, manufacturing and other costs

50.00%

Percentage of closeout project cost

50.00%

Biodesix | FOCAL study | Maximum

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Funding

$ 15,000,000

Biodesix | FOCAL trial

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, royalties payment on net sales

10.00%

Amounts due from pursuant to the cost-sharing provisions

800,000

1,100,000

800,000

1,100,000

Cash received related to cost reimbursements

2,800,000

4,200,000

Biodesix | FOCAL trial | Research and development

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions

2,500,000

3,500,000

2,700,000

Astellas Pharma Inc. | Astellas Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Amounts due from pursuant to the cost-sharing provisions

$ 100,000

$ 100,000

100,000

100,000

Astellas Pharma Inc. | Astellas Agreement | Research and development

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions

300,000

700,000

3,500,000

Astellas Pharma Inc. | Collaboration and License Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, payment received

300,000

1,500,000

4,100,000

Biogen Idec International GmbH

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, deferred revenue

$ 14,700,000

Collaborations and license agreements, revenue recognized

14,100,000

Collaborations and license agreements, relative selling price of the deliverable

$ 600,000

Biogen Idec International GmbH | Maximum

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Royalty payments

50,000,000

Biogen Idec International GmbH | Option and License Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, revenue recognized

$ 38,000

$ 300,000

$ 14,500,000

St Vincent's Hospital Sydney Limited

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Amendment agreement date

2015-08

License fees payable

$ 18,900,000

Collaborations and license agreements, milestone payment

$ 400,000

St Vincent's Hospital Sydney Limited | Licensing Agreements | Up-front Payment Arrangement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, cash payment

$ 1,500,000

Kyowa Hakko Kirin | Utilization of Data Generated by Planned Phase Three Study | Maximum

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Research and development reimbursement payment not required to be paid

$ 20,000,000

Kyowa Hakko Kirin | Phase One Combination Study | Maximum

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Research and development reimbursement payment not required to be paid

2,000,000

Kyowa Hakko Kirin | Licensing Agreements

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, cash payment

5,000,000

Collaborations and license agreements, milestone payment

$ 10,000,000

Collaborations and license agreements, potential future milestone payments, maximum amount

$ 18,000,000

Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements

30.00%

Reimbursement of Research and development milestone

$ 4,000,000

Term of royalty payment obligations

12 years

Kyowa Hakko Kirin | Licensing Agreements | FDA Marketing Approval

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, milestone payment

$ 12,000,000

Kyowa Hakko Kirin | Collaboration and License Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and license agreements, up-front license payment received

$ 22,500,000

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Professional fees	$ 464	$ 573
Compensation and benefits	891	938
Restructuring		357
Other	176	272
Other accrued liabilities	$ 1,531	$ 2,140

Loans Payable - Additional Info

Loans Payable - Additional Information (Detail)	1 Months Ended		12 Months Ended
	May 31, 2016USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Dec. 31, 2016USD ($)Installmentshares	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Loan payable, end-of-term payment due			$ 690,000
Warrants issued to lenders as part of new loan agreement, shares of common stock to purchase | shares	1,202,117	608,696	259,067
Warrants issued to lenders as part of new loan agreement, exercise price | $ / shares	$ 0.87	$ 1.15
Warrants issued to lenders as part of new loan agreement, fair value	$ 700,000	$ 400,000	$ 667,000	$ 413,000
Warrants exercised | shares			0
Unamortized discount recognized			$ 997,000		$ 500,000
Maximum amount of debt conversion			2,000,000
Cash proceeds from issue of units			200,000
Loans Payable | Minimum
Debt Instrument [Line Items]
Option to purchase equity, net cash proceeds of equity securities			$ 10,000,000
Loans Payable | Hercules Amended Loan Agreement
Debt Instrument [Line Items]
Proceeds from additional borrowing capacity		$ 10,000,000
Loan payable, Commencement date		May 1, 2016
Loan payable, due date			Jan. 1, 2018
Loan payable, end-of-term payment due			$ 500,000
Loan issuance costs paid			$ 200,000
Loan payable, description of interest rate terms			Per annum interest is payable on the principal balance of the loan each month it remains outstanding at the greater of 11.9% and an amount equal to 11.9% plus the prime rate minus 4.75% as determined daily, provided however, that the per annum interest rate shall not exceed 15.0% (11.9% as of December 31, 2016).
Loan payable, interest rate, base rate			11.90%
Loan payable, interest rate, additional rate deducted from base rate			4.75%
Loan payable, interest rate			11.90%
Debt instrument convertible beneficial conversion feature			$ 0
Loans Payable | Hercules Amended Loan Agreement | Minimum
Debt Instrument [Line Items]
Loan payable, interest rate			11.90%
Loans Payable | Hercules Amended Loan Agreement | Maximum
Debt Instrument [Line Items]
Loan payable, interest rate			15.00%
Loans Payable | Hercules May 2016 Loan Agreement
Debt Instrument [Line Items]
Proceeds from additional borrowing capacity	5,000,000
Loan payable, Commencement date			Jul. 1, 2017
Loan payable, due date			Dec. 1, 2019
Loan payable, end-of-term payment due			$ 200,000
Loan issuance costs paid			100,000
Loan outstanding principal amount	$ 15,000,000		$ 20,000,000
Loan payable, number of installments of principal and interest | Installment			30
Loan payable, frequency of installments of principal and interest			Monthly payments of principal and interest
Unrestricted and unencumbered cash and cash equivalents			$ 25,000,000
Additional borrowing capacity			$ 5,000,000
Loan payable, Commencement date deferred by six months			Jan. 1, 2018
Loans Payable | Hercules May 2016 Loan Agreement | Financial covenant | Minimum
Debt Instrument [Line Items]
Unrestricted and unencumbered cash and cash equivalents			$ 10,000,000

Future Minimum Payments Under L

Future Minimum Payments Under Loans Payable (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
2,017	$ 4,386
2,018	7,506
2,019	7,159
Long-term Debt, Gross, Total	19,051
Less amount representing interest	(3,361)
Less unamortized discount	(997)	$ (500)
Less deferred charges	(690)
Less loans payable current, net of discount	(2,124)	(2,053)
Loans payable, net of current portion and discount	$ 11,879	$ 7,418

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2016	Dec. 31, 2016	Dec. 31, 2015	May 07, 2015	Mar. 31, 2015	Feb. 28, 2015
Class Of Stock [Line Items]
Common stock, shares authorized		200,000,000	200,000,000
Common stock, par value		$ 0.001	$ 0.001
Common stock, sold		75,862,946	58,182,000
Common stock, shares outstanding		75,862,946	58,182,000
Warrants exercise price		$ 0
Warrant liability		$ 9,300,000
Decrease in the fair value of warrant liability		4,800,000
Common stock sales agreement, aggregate offering amount		$ 76,000	$ 58,000
Offering, issuance and sale of stocks and securities, shelf registration					$ 250,000,000
Sale of stock		0
Maximum
Class Of Stock [Line Items]
Offering, issuance and sale of stocks and securities, shelf registration				$ 100,000,000
F B R Co
Class Of Stock [Line Items]
Common stock, sold		5,900,000
proceeds from sale of shares		$ 10,200,000
Common stock available for sale under Sales Agreement		$ 9,100,000
F B R Co | Maximum
Class Of Stock [Line Items]
Common stock sales agreement, aggregate offering amount				$ 15,000,000		$ 17,900,000
Common stock sales agreement commission, percentage						3.00%
PIPE Warrants [Member] | Private Placement
Class Of Stock [Line Items]
Common stock, sold	17,642,482
Shares issued, price per share	$ 0.965
Gross proceeds from issuance of private placement	$ 17,000,000
Exchange of unit to share	1
Warrants exercise price	$ 1
Warrants exercisable period	5 years
Director and Executive Officer | PIPE Warrants [Member] | Private Placement
Class Of Stock [Line Items]
Common stock, sold	544,039
Net offering proceeds to the company	$ 15,400,000

Key Assumptions Used to Value t

Key Assumptions Used to Value the PIPE Warrants (Detail) - PIPE Warrants [Member] - $ / shares	1 Months Ended	12 Months Ended
	May 31, 2016	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected price volatility	76.25%	78.18%
Expected term (in years)	5 years	4 years 6 months
Risk-free interest rates	1.22%	1.93%
Stock price	$ 0.89	$ 0.54

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	1 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2013	Feb. 28, 2010	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance					8,500,000
Shares available for future issuance under the Plan					2,746,513
Stock options issued to purchase common stock					4,858,678	4,796,005
Total unrecognized stock-based compensation expense related to stock options granted					$ 800,000
Stock-based compensation expense					$ 999,000	$ 1,132,000	$ 2,808,000
Employee Stock Purchase Plan, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance					764,000
Shares available for future issuance under the Plan					307,282
Employee stock purchase plan, number of shares authorized to sell		250,000
Common stock price per share percentage as of lower of fair market value of the common stock		85.00%	85.00%	85.00%		85.00%	85.00%
Employee stock purchase plan, each offering period	6 months
Employee stock purchase plan, number of share sold					0	7,138	139,032
Price per share of shares sold to employees			$ 0.75	$ 1.53		$ 1.07	$ 0.71
Stock-based compensation expense					$ 2,000	$ 27,000	$ 200,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards, vesting period					4 years
Awards, Expiration period					10 years
Weighted-average grant date fair value of stock options granted					$ 0.65	$ 0.75	$ 1.15
Share based payment award forfeiture rates					76.00%	71.00%	62.00%
Total unrecognized stock-based compensation expense, weighted-average period Recognition					2 years 6 months
Intrinsic value of options exercised					$ 6,000	$ 58,000	$ 0
Awards With Market Conditions
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options issued to purchase common stock					197,650
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted stock awards vested					$ 100,000	$ 100,000	$ 200,000
Minimum | Stock Options | Participants Who Own Less than 10% of Total Combined Voting Power
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of incentive stock options as percentage of fair market value of common stock on the date of the award					100.00%
Minimum | Stock Options | Participants Who Own More than 10% of Total Combined Voting Power
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of incentive stock options as percentage of fair market value of common stock on the date of the award					110.00%

Stock Option Activity (Detail)

Stock Option Activity (Detail)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Options
Outstanding at beginning of period | shares	4,796,005
Granted | shares	1,781,134
Exercised | shares	(38,749)
Forfeited | shares	(1,679,712)
Outstanding at end of period | shares	4,858,678
Vested or expected to vest at December 31, 2016 | shares	3,043,129
Exercisable at December 31, 2016 | shares	2,327,806
Weighted-Average Exercise Price
Outstanding at beginning of period | $ / shares	$ 3.78
Granted | $ / shares	1.01
Exercised | $ / shares	0.84
Forfeited | $ / shares	5.17
Outstanding at end of period | $ / shares	2.31
Vested or expected to vest at December 31, 2016 | $ / shares	3.04
Exercisable at December 31, 2016 | $ / shares	$ 3.63
Weighted-Average Remaining Contractual Term
Outstanding at December 31, 2016	7 years 11 months 23 days
Vested or expected to vest at December 31, 2016	7 years 7 months 17 days
Exercisable at December 31, 2016	7 years 4 months 2 days

Assumptions Used in Black Schol

Assumptions Used in Black Scholes Pricing Model for New Grants (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility factor, minimum	72.18%	73.04%	69.38%
Volatility factor, maximum	74.47%	78.70%	77.92%
Risk-free interest rates, minimum	1.07%	1.54%	1.81%
Risk-free interest rates, maximum	2.01%	1.93%	2.02%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	3 years	5 years 6 months	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 3 months	6 years 3 months	6 years 3 months

Restricted Stock Activity (Deta

Restricted Stock Activity (Detail)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Number of Shares
Unvested at beginning of period | shares	42,750
Vested/Released | shares	(42,750)
Weighted-Average Fair-Value
Unvested at beginning of period | $ / shares	$ 1.61
Vested/Released | $ / shares	$ 1.61

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	May 09, 2012USD ($)ft²	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Commitment And Contingencies [Line Items]
Rent expense		$ 600,000		$ 4,100,000
Rent credit			$ (9,100,000)
Maximum
Commitment And Contingencies [Line Items]
Severance and bonus payment period		18 months
Severance and bonus payment period		18 months
Minimum
Commitment And Contingencies [Line Items]
Severance and bonus payment period		12 months
Severance and bonus payment period		6 months
BMR-650 E KENDALL B LLC
Commitment And Contingencies [Line Items]
Lease agreement, square feet of property leased | ft²	126,065
Lease agreement, initial term	12 years 7 months
Operating lease, maximum lease improvements reimbursement amount	$ 14,900,000
Operating lease, rent expense			(9,500,000)	4,300,000
Recognition of deferred rent credits			10,600,000	3,800,000
Lease Cancellable Arrangement
Commitment And Contingencies [Line Items]
Rent expense			$ 200,000
Restructuring and lease exit
Commitment And Contingencies [Line Items]
Rent expense				$ 3,100,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Operating loss carryforwards, net		$ 4.1
Increase in valuation allowance		10.6	$ 3.9	$ 18.6
State and Local Jurisdiction
Income Taxes [Line Items]
Operating loss carryforwards, net		366.9
Research and development tax credit carryforwards		$ 4.2
State and Local Jurisdiction | Minimum
Income Taxes [Line Items]
Operating loss carryforwards, expiration year		2,030
Research and development tax credit, expiration year		2,019
State and Local Jurisdiction | Maximum
Income Taxes [Line Items]
Operating loss carryforwards, expiration year		2,036
Research and development tax credit, expiration year		2,031
Internal Revenue Service (IRS)
Income Taxes [Line Items]
Operating loss carryforwards, net		$ 476.2
Research and development tax credit carryforwards		$ 10.3
Internal Revenue Service (IRS) | Minimum
Income Taxes [Line Items]
Operating loss carryforwards, expiration year		2,024
Research and development tax credit, expiration year		2,023
Internal Revenue Service (IRS) | Maximum
Income Taxes [Line Items]
Operating loss carryforwards, expiration year		2,036
Research and development tax credit, expiration year		2,036
United Kingdom
Income Taxes [Line Items]
Operating loss carryforwards, net		$ 6.7
CANbridge | Licensing Agreements
Income Taxes [Line Items]
Upfront payment, withholding taxes		0.1
Collaborations and license agreements, expected milestone receivable	$ 1	$ 1

Reconciliation of Expected Inco

Reconciliation of Expected Income Tax Benefit (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax computed at federal statutory tax rate	34.00%	34.00%	34.00%
State taxes, net of federal benefit	5.20%	5.30%	5.30%
Research and development credits	1.40%	2.00%	2.60%
Other permanent differences	6.10%	(2.00%)	(0.80%)
Foreign rate differential	(0.10%)	(0.10%)
Foreign withholding taxes	(0.40%)
SEC settlement liability		(9.10%)
Other	(6.60%)	(3.80%)	(5.70%)
Change in valuation allowance	(39.60%)	(26.30%)	(35.40%)
Total	0.00%	0.00%	0.00%

Company Net Deferred Tax Assets

Company Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
NOL carryforwards	$ 182,433	$ 170,200
Research and development credits	13,060	12,721
Deferred revenue	867	1,451
Other temporary differences	4,570	5,935
Valuation allowance	(200,930)	(190,307)
Total	$ 0	$ 0

Reconciliation of Gross Uncerta

Reconciliation of Gross Uncertain Tax Positions (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Amount established upon adoption	$ 1,200	$ 1,200	$ 1,200
Additions for current year tax provisions	0	0	0
Additions for prior year tax provisions	0	0	0
Reductions of prior year tax provisions	0	0	0
Balance as of end of year	$ 1,200	$ 1,200	$ 1,200

Strategic Restructuring - Addit

Strategic Restructuring - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016Position
Restructuring And Related Activities [Abstract]
Restructuring plan, completion date	Mar. 31, 2015
Restructuring plan, percentage of number of positions eliminated	66.67%
Restructuring plan, number of positions eliminated	40

Restructuring Activity Recorded

Restructuring Activity Recorded in Operating Expenses and Accrued Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring amounts accrued, beginning balance	$ 357
Restructuring amounts accrued, ending balance		$ 357
Employee Severance
Restructuring Cost And Reserve [Line Items]
Restructuring amounts accrued, beginning balance	357
Restructuring expense incurred		3,560
Restructuring amounts paid	$ (357)	(3,203)
Restructuring amounts accrued, ending balance		$ 357

Facility Lease Exit - Additiona

Facility Lease Exit - Additional Information (Detail)	May 09, 2012USD ($)ft²	Sep. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Facility Lease Exit Disclosure [Line Items]
Lease exit expense incurred				$ 0
Notice period to surrender remaining leased space				90 days
3rd Amendment, Lease exit costs associated with 650 E. Kendall.
Facility Lease Exit Disclosure [Line Items]
Lease exit expense incurred		$ 15,600,000
Leased space surrendering date				May 29, 2015
3rd Amendment, Lease exit costs associated with 650 E. Kendall. | Leasehold Improvements
Facility Lease Exit Disclosure [Line Items]
Additional charge to depreciation expense due to revision of estimated useful life			$ 2,900,000		$ 2,900,000
3rd Amendment, Lease exit costs associated with 650 E. Kendall. | Deferred Rent And Leasehold Improvement
Facility Lease Exit Disclosure [Line Items]
Additional charge to depreciation expense due to revision of estimated useful life			$ 3,500,000
BMR-650 E KENDALL B LLC
Facility Lease Exit Disclosure [Line Items]
Lease agreement, square feet of property leased | ft²	126,065
Lease agreement, initial term	12 years 7 months
Operating lease, maximum lease improvements reimbursement amount	$ 14,900,000
Operating lease, rent expense					(9,500,000)	$ 4,300,000
Recognition of deferred rent credits					$ 10,600,000	$ 3,800,000

Components of Lease Exit Activi

Components of Lease Exit Activity Recorded in Current Liabilities (Detail) - Lease exit costs $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Facility Lease Exit Disclosure [Line Items]
Lease Exit amounts accrued	$ 4,981
Accretion Expense incurred	224
Amounts paid	(5,477)
Additional expense incurred	$ 272

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
401(k) Plan, matching employer contribution percentage	50.00%
401(k) Plan, employee contributions percentage	5.00%
Contributions made under the plan	$ 0.1	$ 0.1	$ 0.1

Summary of Quarterly Results (D

Summary of Quarterly Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Collaboration and licensing revenue	$ 127	$ 992	$ 193	$ 1,203	$ 3,598	$ 15,158	$ 134	$ 134	$ 2,515	$ 19,024	$ 18,123
Restructuring and lease exit							25	4,333		4,358	11,729
Operating expenses	9,553	6,585	7,335	8,435	9,721	6,691	4,730	5,950
(Loss) income from operations	(9,426)	(5,593)	(7,142)	(7,232)	(6,123)	8,467	(4,621)	(10,149)	(29,393)	(12,426)	(50,449)
Change in fair value warranty liability	4,569	1,178	(996)						(4,751)
Other expense, net	(748)	(551)	(468)	(378)	(462)	(553)	(835)	(725)	2,607	(2,575)	(2,290)
Net (loss) income	$ (5,605)	$ (4,966)	$ (8,606)	$ (7,710)	$ (6,585)	$ 7,914	$ (5,456)	$ (10,874)	$ (26,887)	$ (15,001)	$ (52,739)
Net (loss) income per share	$ (0.07)	$ (0.07)	$ (0.13)	$ (0.13)	$ (0.11)	$ 0.14	$ (0.10)	$ (0.21)	$ (0.39)	$ (0.27)	$ (1.01)

Legal Proceedings -Additional I

Legal Proceedings -Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)LegalMatter	Dec. 31, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
Class action lawsuits | LegalMatter	2
Attorney fees cost and expenses	$ 822,116
Amount of damages awarded to plaintiff	2,500
Reserve for settlement of fines	$ 4,000,000	$ 4,000,000